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ABSTRACT 
 
The World Health Organisation has estimated that about 219 million cases of malaria occurred in 
2010 with an estimated 660,000 fatalities resulting. The disease is caused by five species of 
protozoan parasites of the genus Plasmodium with Plasmodium falciparum being the most 
virulent. Among the many shortfalls of current antimalarial drugs, the emergence of drug 
resistant strains of the malaria parasites is the most disturbing. Thus, there is an urgent need to 
develop new chemotherapeutic agents which can potentially target drug resistant strains of these 
parasites. Undertaking structure activity relationship (SAR) studies around biologically active 
compounds is one strategy that can identify analogues with superior activity and/or novel modes 
of action to circumvent drug resistance. In this dissertation, the synthesis, characterisation, and 
antiplasmodial evaluation of aminomethylthiazoles and related analogues are reported. 
The target compounds were synthesised by diverse protocols. The aminomethylheteroaryl 
pyrazole carboxamides PCM1-006 and PCM1-012 were synthesised by a three step synthetic 
protocol. This involved an acid-amine coupling step, followed by reduction of the cyano 
functionality and in situ boc-protection of the resulting primary amine. Deprotection with 
trifluoroacetic acid (TFA) delivered the desired aminomethylheteroaryl pyrazole carboxamides. 
A unique protocol was, however, employed to synthesise the lead compound MMV010539. The 
acid-amine coupling step was followed by a nucleophilic substitution of the chloro group with 
the azide group. A Staudinger reduction of the azide gave the free amine. 
Analogues PCM1-031 – PCM1-051, PCM1-083, PCM1-085, and PCM1-087 were synthesised 
by coupling various carboxylic acids to a common amino intermediate followed by the 
deprotection of the amino functionality with TFA. 
The aminomethylthiazole pyrazole carboxamides PCM1-056 – PCM1-073, and PCM1-089 
were synthesised using a different strategy. The first step involved an acid-amine coupling 
reaction, which was followed by an N-benzylation step before deprotection of the amino group 
with TFA.     
The synthesised compounds were characterised by a range of spectroscopic and analytical 
techniques. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), infrared 
(IR) spectroscopy, high performance liquid chromatography (HPLC), thin layer chromatography 
(TLC) and melting point (m.p.) measurements were employed to fully characterise the target 
compounds.  
ix 
 
The synthesised target compounds were assayed for aqueous solubility using the turbidimetric 
solubility assay and were found to have mean solubility values in the range 10 to > 200 µM at 
physiological pH (pH 7.4)  
Relative to the lead compound MMV010539 (IC50 = 0.0203 µM), all the analogues generally 
exhibited inferior in vitro antiplasmodial activity against the drug sensitive strain (NF54) of the 
parasite. The in vitro antiplasmodial activities were in the range IC50 = 0.125 to 173 µM with 
analogue PCM1-006 retaining sub-µM activity (IC50 = 0.125 µM). 
The SAR studies undertaken revealed that the thiazole moiety in the lead compound 
MMV010539 is crucial for potent in vitro antiplasmodial activity but other aromatic 
heterocycles seem tolerable. Replacement of the N-benzylpyrazole moiety was found to be 
detrimental to activity. Moreover, introduction of substituents on the aromatic portion of the 
benzyl group as well as replacement of the tert-butyl group with other substituents was found to 
compromise activity albeit not drastically.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 Malaria: History and Introduction 
The term malaria is derived from an Italian word mal’aria, meaning “bad air” and its occurrence 
can be traced back to about 40 centuries ago with the Chinese, Romans, and Greeks, particularly 
Hippocrates, documenting the symptoms from 2700 BCE – 340CE.1 Ancient Roman infections 
were thought to be the result of walking in the night air.2 Hippocrates later described the 
characteristics of malaria and pointed out its correlation with seasons and location.3 He gave 
insight into the association of malaria with stagnant waters, which later prompted the Romans to 
embark on drainage programs. These preventive measures were amongst the first ones aimed at 
combating malaria in the Roman Empire.3  
For many centuries, malaria has been a major health problem in Europe and Africa. Generally, 
the spread of malaria was fuelled by travelling tradesmen, settlers, and conquering forces. Over 
four centuries of slave trade saw millions of Africans die from the disease and it has been 
thought that the transportation of slaves facilitated the spread of malaria to the New World.3 
Malaria generally thrives in the tropical regions of the world, but it also had a profound impact 
on the early settlers of America, where it was commonly known as the “fever and ague.” In 
1875, its incidence in America peaked, and in 1914 over 600,000 cases were reported.3  
Over the centuries, the understanding of malaria has evolved from myths to a clear scientific 
insight due to ground-breaking advances in medicine and dedicated efforts of individual 
scientists. Charles Louis Alphonse Laveran, a French army surgeon, is credited for discovering 
malaria parasites in the blood of infected patients.4 Camillo Golgi, an Italian neurophysiologist, 
later established the existence of two forms of the disease. He noted that the first form of the 
disease was associated with tertian periodicity – fever every other day. The second form of the 
disease was associated with quartan periodicity – fever every third day. He further established 
that there was a concomitant appearance of the fever symptoms with the rupture of merozoites 
and their release into the blood stream.4 Moreover, the mystery of the transmission of malaria 
was unravelled by Giovanni Batista Grassi and co-workers (1898-1899) who clearly 
demonstrated that the female Anopheles mosquito was responsible for the transmission of 
malaria from one human to another.4    
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The origins of malaria and particularly Plasmodium falciparum (P. falciparum) associated 
malaria, the most severe form of malaria, have been a subject of great controversy. Some studies 
have found Egyptian mummified remains, dating back to 1500-500 BC, containing P. falciparum 
DNA.5 Other studies revealed that malaria originated from gorillas and not humans, which have 
led to the thought that the occurrence of P. falciparum in humans could have been a result of 
transmission from these apes.6  
Malaria has clearly ravaged human populations from time immemorial, and still does today. The 
resurgence of malaria today has been fuelled by the advent of drug resistant parasites, which 
have significantly hampered efforts aimed at control and possible eradication of the disease. The 
recent unravelling of the P. falciparum genome, however, has given hope and promise to 
scientists for the design and development of novel and more effective chemotherapeutic 
remedies to malaria.7 
 
1.2 Malaria epidemiology 
Malaria has continued to be amongst the most devastating infectious diseases of our time and 
closely rivals HIV and tuberculosis (TB) in being a lead killer disease, mainly in tropical and 
subtropical regions (Figure 1.1).8 According to the  World Health Organisation (WHO) 
estimates, about 219 million cases occurred in 2010 (uncertainty range: 154 million to 289 
million) with about 660,000 cases resulting in fatalities (uncertainty range: 490 000 to 836 000).9 
The vast majority of cases (80%) and deaths (91%) occurred in Sub-Saharan Africa with 86% of 
deaths occurring in children under the age of 5.10 Pregnant women are also highly vulnerable. 
About 125 million pregnant women are at risk of malaria infection. In Sub-Saharan Africa, an 
estimated 200,000 infant deaths result from maternal malaria every year.11 Moreover, in Western 
Europe and the United States there are respectively about 10,000 and 1300-1500 malaria cases 
per year.12 In Europe, about 900 people died from the disease between 1993 and 2003.13  
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                                      Figure 1.1 Geographic distribution of malaria14 
 
Malaria transmission is more intense in warmer regions closer to the equator where the malaria 
vector can survive and multiply. High rainfall, humidity and stagnant waters in areas closer to 
the equator provide a conducive environment for continuous breeding of mosquitoes.15 Malaria 
is therefore presently endemic in a broad band around the equator (Figure 1.1). Endemic areas 
include the Americas, many parts of Asia, and much of Africa. P. falciparum, the most virulent 
malaria parasite, however, cannot complete its growth cycle at temperatures below 20 ⁰C. 
Therefore, in cooler regions of the world, transmission is less intense and more seasonal. In 
addition, improved public health measures and economic development in many temperate areas, 
such as Western Europe and the United States of America (USA), have succeeded in combating 
malaria to some extent. Most of these areas, however, have Anopheles mosquitoes which have 
the potential to transmit malaria and hence there is a constant risk of disease reintroduction.16  
Generally, rural areas suffer more incidences of malaria than cities. For instance, the cities of the 
Greater Mekong Subregion of Southeast Asia are essentially malaria free, whereas the disease is 
prevalent in rural parts of this region including international borders. Malaria is, however, 
prevalent in both urban and rural areas in Africa though there is reduced risk in larger cities.17,18 
According to the WHO 2012 world malaria report, malaria is currently endemic in 104 countries. 
In addition, every year around 30,000 out of about 125 million international travellers visiting 
these countries contract the disease.13   
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Global incidences of malaria and resulting mortalities have declined in recent years. According 
to the WHO, about 985,000 deaths were attributed to malaria in 2000. From 2000-2010, 
however, deaths due to malaria decreased by a third mainly as a result of the wide spread use of 
insecticide-treated nets (ITNs) and artemisinin-based combination therapies (ACTs).19 
 
1.3 Malaria Parasite: Biology and Life Cycle 
Four species of Plasmodium parasites are responsible for malaria infection in humans. These 
include P. falciparum, P. vivax, P. malariae, and P. ovale of which P. falciparum and P. vivax 
are the most common. P. falciparum is the most deadly. Recently, P. knowlesi, a malaria parasite 
species that infects monkeys and prevalent in certain forested areas of South-East Asia, has been 
reported to infect humans.20  
Understanding the biology and life cycle of the malaria parasite is key to devising more rational 
control mechanisms and developing chemotherapeutic remedies against the disease.21 The 
biology and life cycle of P. falciparum is the most studied and best understood of the parasites 
that infect humans.22 
 
1.3.1 Life Cycle of the Malaria Parasite 
The malaria parasite naturally infects a human host and a female Anopheles mosquito vector. 
Parasites are transmitted to the human host through a bite by an Anopheles mosquito. Within the 
human host, the parasites grow and multiply in liver cells, before invading red blood cells 
(RBCs). Parasites are transmitted back to the female Anopheles mosquito while in the blood 
stage.23  
Malaria parasites are first introduced into the human host during a blood meal of a female 
Anopheles mosquito. The parasites are introduced as sporozoites, which quickly invade liver 
cells (Figure 1.2). 
In the liver, sporozoites undergo rapid growth and division to produce tens of thousands of 
merozoites per liver cell. This growth and division takes place over 5 – 16 days, depending on 
the specific malaria parasite species.24 It is during the liver stage that some parasite species go 
into dormancy, which results in relapse weeks or months later. The infected hepatocytes (liver 
cells) eventually burst open, releasing merozoites into the blood stream where they begin a cycle 
of invasion of RBCs. In the RBCs, merozoites undergo asexual replication, which results in 
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multiplication and concomitant lysis of the RBCs to release the newly formed merozoites.24 The 
released merozoites attack new RBCs and the cycle of RBC infection continues in this manner. 
The RBC infection cycle completes every 1 – 3 days depending on the parasite species. Blood 
stage multiplication of the parasites eventually leads to thousands of RBCs becoming infected 
and giving rise to the symptoms and complications associated with malaria. The illness and 
complications can last for months if not treated or if the host’s immune system does not 
intervene.24  
 
 
                                        Figure 1.2 Life cycle of the malaria parasite24 
 
During asexual replication, some merozoites develop into sexual male and female gametocytes, 
which continue their circulation in the blood stream. It is these sexual forms of the parasite that 
are ingested into the mosquito when feeding on an infected host.24 Once in the mosquito, 
gametocytes are released into the gut where further development into mature sex cells, called 
gametes occurs. Diploid zygotes are formed following the fusion of male and female gametes. 
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Zygotes develop into mobile ookinetes, which travel to the mosquito midgut where they further 
develop into oocysts (Figure 1.2). After 8 – 15 days,24 depending on the parasite species, the 
oocyst grows and divides, producing thousands of sporozoites which are released into the body 
cavity of the mosquito. The sporozoites invade the salivary glands of the mosquito, ready to 
continue the cycle of human infection. 
 
1.3.2 Biochemistry of the Plasmodium Parasite 
1.3.2.1 Background 
The malaria parasite in the erythrocytes (RBCs) needs to nourish itself with nutrients, which it 
can then convert to other molecules and energy in order to maintain its homeostasis.25a The 
molecules also serve as raw materials for parasite growth and reproduction.25a For the parasite to 
grow and multiply, it needs bulk amounts of macromolecules and other biochemicals to maintain 
cellular structure and function. The parasite unfortunately degrades the host’s macromolecules in 
order to manufacture its own macromolecules and biochemicals. Both the anabolic and catabolic 
processes that take place in the parasite are mediated by its enzymes.25a  
The metabolic pathways of the malaria parasite have evolved over time due to its unique life 
cycle and microenvironment and, therefore, differ significantly from those of its human host.25a 
The presence of unique pathways in the parasite metabolism makes rational target-based drug 
design efforts tenable. In this light, drug or therapeutic strategies could be designed to disrupt 
unique parasite metabolic pathways. Some antimalarials are for instance known to cause parasite 
death by accumulating in the food vacuole (FV) which is a specialised parasite organelle for 
digestion of host haemoglobin (Hb).25a  
 
1.3.2.2 The P. falciparum Food Vacuole and Haemoglobin Degradation 
Therapeutic intervention of P. falciparum infection remains of paramount importance as it has 
been implicated in virtually all human malaria deaths.26 P. falciparum and P. vivax are also 
responsible for the majority of infections.26 In addition, the availability of methodologies for in 
vitro culture of P. falciparum for some decades, effected thorough scientific investigation that 
provided a deeper understanding of its biochemistry more than its counterparts (P. vivax, P. 
malariae, P. ovale and P. knowlesi).22 Further discussions around FV biochemistry and Hb 
degradation pathways will be based on the P. falciparum malaria parasite. 
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As the malaria parasite invades the human host, pathogenic effects are only manifested during 
the blood stages of the parasite life cycle. The blood cycle involves four stages of which the 
trophozoite stage is metabolically the most active.27 In the RBCs, the malaria parasite has to 
acquire amino acids in order to synthesise its proteins. The parasite suffers from its incapability 
to synthesise the amino acids in a de novo manner or uptake them exogenously. Consequently, 
the parasite resorts to catabolism of Hb to gain the necessary amino acids for its protein synthesis 
and maturation.28-32 During the trophozoite stage, the parasite ingests and degrades about 60 – 
80% of the Hb initially contained in the RBC.33-35 There is evidence suggesting that only a small 
percentage of these amino acids are actually used for protein synthesis.31,36 It has therefore been 
thought that apart from degrading Hb to obtain amino acids, degradation also serves to create 
space for the parasite within the RBC and to ensure osmotic stability of the RBC.37,38 
The RBC cytosol is first transported into the FV of the parasite via the cytostome and some 
transport vesicles (Figure 1.3).27 
 
 
Figure 1.3 Structure of an infected RBC27 
 
In the FV, Hb undergoes degradation by a series of proteolytic enzymes, which function 
optimally under the acidic conditions of the FV. The FV is widely believed to have a pH in the 
range of 5.0-5.5, though the actual pH and biochemistry of this compartment has recently been 
debated.39-42 Bray et al reported the dependence of the fluorometrically determined pH of the FV 
on the pKa of the fluorophore. Therefore, contrary to what was previously believed, they 
suggested that the pH of this compartment may be variable, or weakly controlled.42 They have 
also radically proposed that the transport vesicles may be the sites for Hb degradation, albeit 
- 8 - 
 
more tangible evidence is required to support this proposition.43 On the other hand, more 
concrete evidence of haemoglobinase enzymes being located in the FV44,45 strongly suggests Hb 
catabolism does indeed occur in the FV, although the process may begin in the transport 
vesicles.46 
Three classes of protease enzymes have been identified in the FV. The first class is a group of 
four aspartic proteases, which comprise of plasmepsins-I, II and IV, and histo-aspartic protease 
(HAP).44 The second class is a group of three cysteine proteases, generally referred to as 
falcipains, and includes falcipains-I, II and III.47 The third class is represented by a zinc 
metalloprotease called falcilysin.48  
Complete Hb degradation is accomplished by the sequential action of all three classes of 
proteolytic enzymes (Figure 1.4).49a However, there remains uncertainty on the physiological 
role of falcipain I in asexual blood stages of the parasite.49b 
 
 
Figure 1.4 Hb degradation path way in the parasite FV25 
 
Undenatured Hb is susceptible to cleavage by plasmepsins-I and II between phenylalanine and 
leucine residues at positions 33 and 34 of the alpha-globin chains.45,50 The region on the globin 
chains on which the two residues are located is believed to be very important in giving stability 
to the overall Hb structure.45,50 This cleavage causes the globin subunits to dissociate (Figure 
1.4) and partially unfold, thereby exposing more protease sites to degradation. Further 
degradation, mediated by other plasmepsins, including falcipains, therefore, occurs on the large 
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globin fragments (Figure 1.4). Falcipain-II and possibly falcipain-III, have the capability of 
digesting native Hb, and have, therefore, been thought to be involved in the initial cleavage of 
Hb.45,50 Falcilysin however, lacks the ability to digest either native Hb or denatured globin.25a It 
does however, cleave polypeptides produced from the action of the plasmepsins and 
falcipains.25a The action of falcilysin results in the formation of small peptides containing 6-8 
amino acids (oligomers), which are further broken down to free amino acids by amino peptidases 
in the FV (Figure 1.4).51 It has also been shown that a neutral amino peptidase activity occurs in 
the cytoplasm of several Plasmodium species,52,53 implying that some of the peptide oligomers 
are transported out of the FV to the parasite cytoplasm prior to their digestion.54  
In summary, the overall process of Hb digestion process seems to involve initial break down of 
Hb into large fragments by plasmepsins-I and II (and possibly falcipain-II). Combinations of 
several plasmepsins and falcipains then carry out further catabolism to smaller polypeptide 
fragments, which are further acted on by falcilysin. Amino peptidase enzymes finally hydrolyse 
the small peptides into free amino acids (Figure 1.4).25a 
More recently, an important aspartic protease enzyme critical for parasite viability, plasmepsin-
V, has been implicated in the cleavage of 200-300 effector proteins at a common conserved site 
[Plasmodium export element (PEXEL) motif]. This cleavage facilitates export of effector 
proteins out of the parasite into the cytosol of the infected erythrocyte,25b,25e thereby altering 
certain properties of the host RBC. Such altered properties include permeability to a number of 
substances, enhanced rigidity, and adherence to endothelial cells.25c Contrary to the plasmepsins 
that have been previously characterised and reported in literature as well as discussed in this 
dissertation, plasmepsin-V has been associated with a physiologically distinct role25d and is 
considered an interesting enzyme for antimalarial drug development.25b Moreover, unlike 
plasmepsins-I, II and IV, which are located in the FV,44 plasmepsin-V’s location is in the 
endoplasmic reticulum (ER) of the parasite, makes its participation in haemoglobin degradation 
highly unlikely.25d  
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1.3.2.3 Detoxification of Haem 
The process of Hb degradation releases haem (ferroprotoporphyrin IX or Fe(II)PPIX) (Figure 
1.5).55 The iron centre of haem undergoes oxidation, likely through spontaneous autoxidation by 
molecular oxygen, which results in the formation of haematin (aqua/hydroxoferriprotoporphyrin 
IX or H2O/HOFe (III)PPIX) (Figure 1.6).
46                                                                                                                                                                                                   
 
Figure 1.5 Structure of Haem 55 
 
Haem has been shown to be toxic to various organisms ranging from bacteria to vertebrates.56,57 
Vertebrates, however, have specialised defence proteins called haemopexins, which counteract 
these toxic effects by sequestration of free haem. It, therefore, seems logical to conclude that the 
malaria parasite must possess a defence mechanism against the toxic effects of haematin. It has 
been known for over a century that haematin gets converted into haemozoin.46,58 Haemozoin is a 
microcrystalline substance with poor solubility present in the FV of the parasite.46 Great strides 
have recently been made to unravel the fate of haem in the malaria parasite quantitatively by 
Egan and co-workers.46 
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Figure 1.6 Hb degradation and Haem detoxification path way in the parasite FV32 
 
Some studies have led to the conclusion that only 30% of the iron obtained from Hb degradation 
is sequestered in haemozoin.33,34 It was on this initial finding, that Ginsburg and co-workers 
based their hypothesis that the remaining haematin undergoes transportation out of the FV into 
the parasite cytosol, where it undergoes degradation in a glutathione-dependent process.33 It has 
also been shown that such a process is chemically feasible.59 However, Tilley and co-workers 
have maintained that hydrogen peroxide generated by the autoxidation of haem is responsible for 
the degradation of haematin, and that this degradation occurs in the FV (Figure 1.6).34 On the 
other hand, a study employing three independent physical and chemical techniques (Colorimetry, 
Mössbauer spectroscopy, and electron spectroscopic imaging) conclusively established that at 
least 95% of the haem generated through Hb degradation is incorporated into haemozoin.60 
Degradation of a small portion of haem, however, cannot be ruled out.  
 
1.4 Malaria Control, Prevention and Treatment 
A number of strategies have been employed in an attempt to control and prevent transmission of 
malaria. These range from vector control programmes to prophylactic and other 
chemotherapeutic remedies. 
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1.4.1 Current Preventive Measures 
Prevention of infection and transmission plays a pivotal role in the fight against malaria. A 
number of preventive measures are employed in an effort to protect individuals in disease 
endemic areas.61 
 
1.4.1.1 Vector Control Programmes 
Mosquito vector control strategies are aimed at reducing the mosquito population. They 
incorporate the use of household insecticide indoor residual spraying (IRS), larval control, and 
insecticide treated nets (ITNs). With the availability of effective insecticides against adult 
Anopheles mosquitoes, IRS and ITNs have become the most valuable mosquito vector control 
measures.62 Before dichlorodiphenyltrichloroethane (DDT) was known, the eradication and 
control of malaria in several tropical areas was achieved by removal or poisoning of mosquito 
breeding grounds, and the aquatic habitats of larva stages. For example, places with standing 
water were filled or had oil applied on them. However, for over half a century, there has been 
little application of these eradication methods in Africa.61 
 
1.4.1.2 Prophylaxis 
Prophylaxis is another strategy employed in the prevention of malaria. This involves 
administration of drugs on a daily or weekly basis to prevent possible infection. Contrary to the 
treatment of a malaria patient, prophylactic administration of drugs is done at a much lower 
dose.61 However, in malaria endemic areas this practice is impractical owing to the exorbitant 
cost of the drugs and negative side effects associated with long term use.61 These factors, 
coupled with the difficulty to obtain effective antimalarial drugs in poor countries hamper the 
prophylactic use of antimalarial drugs in malaria endemic areas.61 Prophylactic use of 
antimalarial drugs is therefore restricted to individuals travelling to malarial regions on a short 
term basis.61 
Mefloquine (MFQ) (Lariam), doxycycline (DX), and the combination of atovaquone 
(ATQ) and proguanil (PG) hydrochloride (Malarone) are some of the preventive drugs in 
modern use.61 Parasite resistance in the area to be visited, side effects, and other considerations, 
have to be taken into account when choosing the drug for prophylactic use.61 It is also important 
to note that the prophylactic effect takes some time to begin after starting taking the drugs. 
Temporary visitors to malaria endemic regions therefore have to start taking prophylactic agents 
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one to two weeks prior to their arrival. The medication must also continue for four weeks after 
leaving malaria endemic zones.61 ATQ and PG combinations are the exception in that 
medication has to start two days before the visit and only continued for seven days afterwards.61 
 
1.4.1.3 Vaccination 
There is currently no effective vaccine against malaria, but a variety of candidates are under 
development.61 However, vaccine development has largely been hampered by the complex 
nature of the malaria parasite.61 The most clinically advanced vaccine candidate, RTS,S/AS01, 
has recently undergone large scale phase III trials and has been found to protect children as well 
as infants from clinical malaria for up to 18 months after vaccination. The WHO has since 
indicated the possibility of a policy recommendation for RTS,S/AS01 as early as 2015.63 The 
largest group of vaccines being researched are pre-erythrocytic vaccines which target the parasite 
before it reaches the blood stages. Other groups of vaccine candidates are also being 
investigated.61 
 
1.4.1.4 Other methods 
Education in recognising the symptoms of malaria in endemic areas has played a critical role in 
the fight against the disease. In some areas of East Africa for example, education resulted in the 
reduction of the number of cases by as much as 20%.61 People are also informed through 
education of the need to cover areas of stagnant and still water, which are ideal breeding grounds 
for mosquitoes.61 
Computing power has also come on board in the fight against malaria. Health effects and 
transmission dynamics of the disease have been simulated in an attempt to come up with the best 
method, or combination of methods for malaria control.61 Other approaches to malaria control 
include the use of natural predators for larval control, case management (diagnosis and 
treatment), and mass drug administration including mass fever treatment.64,65 
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1.4.2 Chemotherapeutic Interventions and Challenges 
1.4.2.1 Introduction 
Malaria has been one of the worst public health problems which has ravaged humankind for 
centuries. The situation was exacerbated by the lack of specific treatments for this disease for 
many centuries.66 In the 17th century, quinine (QN) was successfully extracted from a tree bark 
from Peru,  and in turn gave rise to the development of other synthetic alternatives. Of these 
synthetic alternatives, chloroquine (CQ) was the most successful antimalarial, but it suffered 
widespread resistance by the 1970s. The antimalarial drug artemisinin came on the scene in the 
same decade when Chinese scientists extracted it from the sweet wormwood plant. Artemisinin 
has since been very effective against chloroquine resistant parasites. With the effective use of 
ACTs, there has been renewed hope for the eradication of malaria.66 However, the emergence of 
multidrug resistant (MDR) strains of P. falciparum has rendered antimalarial chemotherapy 
challenging and complex.66,67 For example, affordable antimalarial drugs such as CQ and 
sulphadoxine-pyrimethamine (SP) have suffered widespread resistance hampering the fight 
against malaria. Because of their low cost and availability, these drugs still find use in Africa, 
albeit 30% of treatments fail. For countries were resistance to conventional monotherapies such 
as CQ or SP is evident, the WHO has recommended the use of ACTs for P. 
falciparum malaria.68 Because of being costly however, the artemisinins have limited use in the 
developing world.69 Moreover, disturbing evidence has emerged suggesting the existence of 
malaria parasites resistant to combination therapies that include artemisinins.70,71  
There seems to be hope for malaria chemotherapy with recent ground-breaking advances such as 
the successful sequencing of the P. falciparum genome. The genomics of P. falciparum is 
expected to play a crucial role in the development of new therapeutic approaches.72-74 In 
addition, understanding of the biochemistry of the P. falciparum parasite has led to unravelling 
the modes of action of current antimalarial drugs, and also has helped to identify novel potential 
therapeutic targets.75,76 
 
1.4.2.2 Classification of Clinically Established Antimalarial Drugs 
The current antimalarial drugs in clinical use can be classified according to their mode of 
action.77,78 They can also be classified on the basis of the malaria parasite life cycle stage they 
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therapeutically act on in the human host.77,78 The later classification will be discussed in greater 
detail. 
 
1.4.2.2.1 Classification based on Parasite Life Cycle Stage Targeted 
Antimalarial drugs can be classified into five groups according to their therapeutic action on the 
relevant malaria parasite life cycle stage. These groups include causal prophylactic drugs, 
schizontocidal drugs, gametocytocidal drugs, sporontocidal drugs, and anti-relapse drugs or 
secondary tissue schizontocides.79 
    
i) Causal prophylactic drugs. Also called primary tissue schizontocides, these drugs are known 
to act on the primary tissue phase (pre-erythrocytic forms) of the malaria parasite.79 Primaquine 
(PQ), pamaquine (PM) and possibly quinocide (QC) (Figure 1.7) are examples of drugs that act 
on primary tissue schizonts of P. falciparum and P. vivax. However, their use as prophylactic 
drugs is impractical due to possible side effects. Proguanil (PG) hydrochloride and 
pyrimethamine (PY) (Figure 1.7) on the other hand, possess higher activity against primary 
tissue forms of P. falciparum. They are also known to have some activity on the primary tissue 
forms of P. vivax.79 
 
ii) Schizontocidal drugs. These drugs are also known as blood schizontocides and have 
therapeutic action against all species of malaria parasites on the asexual erythrocytic stage. 
Typical schizontocidal drugs include QN, mepacrine (MEP), CQ, and amodiaquine (AQ) 
(Figure 1.7). Owing to their potency and rapid action, these drugs find use in the treatment and 
temporary prevention (suppression) of clinical symptoms associated with malaria.79  
 
iii) Gametocytocidal drugs. The 8-aminoquinolines, such as PM, PQ, and QC outlined in figure 
1.7, are the most active of this class of antimalarials.79 These act on the sexual forms of all 
species of malaria parasites with PQ and QC being much less toxic than the others. Other 
antimalarials such as AQ, CQ, MEP, and QN (Figure 1.7), also possess activity against the 
sexual forms of P. malariae and P. vivax, but are devoid of direct activity on the gametocytes of 
P. falciparum.79 
iv) Sporontocidal drugs. The antimalarial activity of these drugs arises from their inhibition of 
parasite development at the sporogonic phase in the mosquito. PG, chloroproguanil, and 
- 16 - 
 
particularly PY are some examples of antimalarial drugs that exert this " anti-sporogonic action " 
effect.79  
v) Anti-relapse drugs (secondary tissue schizontocides). The activity of these drugs is mainly 
on the secondary exo-erythrocytic phase of P. vivax and P. malariae infections in the liver. PM, 
PQ, and QC are the only antimalarial drugs with high enough activity. Usually, administration of 
these drugs is done after treatment of the primary attack and they are responsible for the cure of 
all relapsing infections. However, these drugs can also be administered at the time of latency or 
during a relapse.79 
 
 
Figure 1.7 Chemical structures of drugs acting on different parasite life cycle stages  
 
In conclusion, malaria remains a major cause of death for the impoverished countries of Sub-
Saharan Africa and other tropical regions. Poverty and poor living conditions in Sub-Saharan 
Africa have exacerbated the situation. Antimalarial drug development programmes need to take 
this fact into account and ensure drugs that finally make it to the clinic are affordable. Resistance 
to antimalarial drugs no matter how novel they act also seems to be an inevitable fact. This calls 
for continued drug discovery efforts to identify new generations of antimalarial agents. Many 
classes of compounds have shown promise as novel antimalarial agents. These include 
compounds containing the thiazole heterocycle which are the central focus of the next chapter. 
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CHAPTER 2 
THIAZOLES AND RELATED DERIVATIVES AS ANTIMALARIAL AND 
ANTIPLASMODIAL AGENTS 
 
2.1 Introduction 
The main objective of this MSc research project was to expand structure activity relationship 
(SAR) studies of aminomethylthiazole analogues as antiplasmodial agents. SAR studies around 
the lead compound MMV010539 (Figure 2.1) would also serve to identify other analogues with 
improved potencies and devoid of the liabilities (moderate potential to inhibit cytochrome P450 
1A2 (CYP1A2) and cytochrome P450 2D6 (CYP2D6) and potential human Ether-à-go-go-
Related Gene (hERG) liability)1 of the aforementioned lead compound. In this chapter, the 
antiplasmodial and antimalarial activity of MMV010539 and other thiazole derivatives, in 
general, is discussed. 
 
 
Figure 2.1 Chemical structure of MMV0105391 
 
2.2 Introduction to Thiazoles 
Many biologically potent molecules have been found to contain a thiazole moiety, including 
Sulfathiazole (antimicrobial drug), Abafungin (antifungal drug), Ritonavir (antiretroviral drug), 
and Tiazofurin (antineoplastic drug) (Figure 2.2) to name a few.2,3 Recent drug development in 
various therapeutic areas, such as treatment of allergies,4 hypertension,5 inflammation,6 
schizophrenia,7 bacterial infection,8 HIV infection,9 and hypnotics,10 has utilised thiazole 
derivatives. More recently, thiazole derivatives have found application as new bacterial DNA 
gyrase B inhibitors and as antagonists of fibrinogen receptor (antithrombotic activity).11,12 
Moreover, thiazole derivatives have shown promise as potential antimalarial agents.13-15 
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Thiazoles, therefore, represent an important class of heterocyclic compounds in many therapeutic 
areas. 
 
 Figure 2.2 Chemical structures of drugs with a thiazole moiety 
 
2.3 Thiazole Derivatives as Antimalarial and Antiplasmodial Agents 
2.3.1 Thiazole Derivatives Inhibiting P. falciparum Cysteine Proteases 
The understanding of the biochemistry of the most virulent causative agent of malaria, P. 
falciparum, has led to the identification of various novel potential therapeutic targets.16,17 Among 
the well established chemotherapeutic targets are falcipain-II and falcipain-III, which are 
plasmodial cysteine proteases implicated in Hb digestion in P. falciparum.18-20 Based on the 
reported model structures of falcipain-II21 and falcipain-III22, Goud et al. have employed de novo 
drug design approaches to design and synthesise several trisubstituted thiazole analogues.13 
Through in vitro enzyme inhibition studies, analogue 14, possessing dual activity against both 
falcipain-II and falcipain-III, was identified (Figure 2.3). 
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           Figure 2.3 Trisubstituted thiazole analogue inhibiting falcipain-II and falcipain-III13 
 
Owing to its dual inhibition of the key enzymes of P. falciparum, analogue 14 represents a 
chemical scaffold which could potentially possess antimalarial activity. 
    
2.3.2 Thiazole-derived Amino Acids: Plasmepsin Inhibitors 
The reported drug resistance of the malaria parasites to all classes of antimalarial drugs currently 
in clinical use has given impetus to research efforts aimed at the design and development of 
antimalarials with novel modes of action.23 Because plasmepsins in the parasite FV are crucial to 
Hb degradation in the human erythrocyte,24-26 these enzymes have been the central focus of 
various target based drug design efforts.27-33  
Recently, Karade et al. have reported the design, synthesis and antiplasmodial evaluation of 
thiazole-derived amino acids (Figure 2.4).14 Of all the derivatives evaluated, 3f and 3g (Figure 
2.4) were the most potent against both chloroquine susceptible (CQS) and chloroquine resistant 
(CQR) strains of P. falciparum. The two derivatives were also found to dock to the active site of 
plasmepsin-II,14 suggesting that they could be exerting their antiparasitic activity through 
inhibition of the plasmepsin-II enzyme. 
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                   Figure 2.4 Thiazole-derived α-amino acids with antiplasmodial activity14  
 
2.3.3 Other Thiazole Derivatives with Antiplasmodial and Antimalarial Activity 
Thiazolium salts and their derivatives have shown potential as the next generation of effective 
antimalarials with novel mechanisms of action. Bisthiazolium compounds have recently been 
found to possess exceptionally high potencies and have been designed to inhibit phospholipid 
metabolism in a way that mimics choline.34-38 T3 (Figure 2.5) is one such bisthiazolium 
compound and is currently undergoing clinical trials.15 
  
 
    Figure 2.5 Chemical structure of bisthiazolium salt T3 currently in clinical development15 
 
However, bisthiazolium salt T3 suffers the setback that because of the permanent cationic 
charges, it has limited capability to cross the gastrointestinal barrier and as a result, has low oral 
bioavailability.15 Remedial measures aimed at improving oral bioavailability have been 
undertaken through the synthesis of bisalkylamidines as bioisosteric analogues.39,40 Many other 
thiazole derivatives in the likes of 2,4-diarylthiazoles,41 2,5-bis[amidinoaryl]thiazoles42 have 
been studied and found to possess antiplasmodial activity. 
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2.3.4 Aminomethylthiazoles as Antimalarials 
Aminomethylthiazoles represent another novel class of thiazole derivatives with potential clean 
pharmacology and in vitro as well as in vivo antiplasmodial potency. Recent high throughput 
whole cell screening of a Biofocus SoftFocus kinase library containing over 36000 compounds 
led to the uncovering of an aminomethylthiazole pyrazole carboxamide lead MMV010539 
(Figure 2.6). 
 
 
Figure 2.6 Chemical structure of an aminomethylthiazole pyrazole carboxamide MMV0105391 
 
Owing to its good in vitro antiplasmodial activity against CQ and multidrug resistant strain K1 
(IC50 = 0.08 μM) and CQS NF54 (IC50 = 0.07 μM) compared to CQ (K1 IC50 = 0.194 μM, NF54 
IC50 = 0.016 μM), along with in vivo activity in the P. berghei mouse model, MMV010539 has 
been further explored as a potential antimalarial lead.1 Cytochrome P450 (CYP) profiling of the 
aforementioned lead compound has shown that it has moderate potential to inhibit CYP1A2 
(IC50 = 1.5 μM) and CYP2D6 (IC50 = 0.4 μM). It has also been found to have a potential 
human Ether-à-go-go-Related Gene (hERG) liability (IC50 = 3.7 μM). Preliminary SAR studies 
around MMV010539 have been undertaken to establish which groups of this lead molecule are 
essential for activity (Figure 2.7). 
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                                  Figure 2.7 Preliminary SAR studies on MMV0105391 
 
This SAR study revealed that functionalization or removal of the primary amine generally 
resulted in reduced or loss of antiplasmodial activity. The unsubstituted aminomethyl group was 
also found to be important for potent in vitro activity. Replacement of the pyrazole moiety by 
other aromatic and heteroaromatic groups was detrimental to activity. The scope of structural 
modification of MMV010539, therefore, seems very limited. However, it is clear that thiazoles 
and their derivatives represent an attractive and active area of research as antimalarial agents and 
further exploration is therefore warranted. This dissertation will focus on further exploration of 
SAR around MMV010539. 
 
2.4 Justification of the Study of Thiazole Analogues 
As discussed in the preceding sections 2.3.1-2.3.4, the thiazole moiety is an interesting scaffold 
in antimalarial research and further research is justified for a number of reasons. 
Firstly, some thiazole derivatives have shown inhibition of key proteolytic enzymes of the P. 
falciparum FV and hence show potential as new antimalarials with a potential novel mode of 
action necessary to circumvent drug resistance. Secondly, thiazole derivatives have made great 
strides in antimalarial research as indicated by recent clinical development of T3. Thirdly, 
MMV010539 (Figure 2.6), is a potent antimalarial lead upon which further SAR studies can be 
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based in order to circumvent off-target and cardio-toxicity risks as well as achieve desirable 
pharmacological profiles. 
 
2.5 OBJECTIVE AND AIMS 
The main objective of this MSc study was to expand SAR studies of aminomethylthiazole 
analogues as antiplasmodial agents (Figure 2.8). This investigation is based on synthesising 
analogues in which the main substructure motifs of MMV010539, such as the thiazole moiety 
(SAR 1), the N-benzyl group of the pyrazole moiety (SAR 2), N-benzylpyrazole (SAR 3), and 
the tert-butyl (SAR 4), have been replaced by other groups (Figure 2.8). 
 
 
                                 Figure 2.8 Proposed SAR summary on MMV010539 
 
From the suggested SAR expansion, the following analogues were chosen as specific synthetic 
targets due to synthetic accessibility (Figure 2.9). 
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                                 Figure 2.9 Chemical structures of target compounds. 
 
Synthetic routes towards these targets were designed such that each SAR collection could readily 
be obtained. 
To achieve the overall objective, this study focused on a number of specific aims: 
Firstly, target compounds would be synthesised, characterised, and submitted for antiplasmodial 
evaluation. Secondly, solubility profiling of the target compounds would be done in parallel with 
antiplasmodial evaluation. Solubility is an important physicochemical parameter to establish as it 
impacts gastrointestinal absorption of oral drugs. Generally, low solubility of oral drugs can lead 
to suboptimal oral bioavailability, lack of efficacy, abnormal PK profiles, toxicity of vehicles 
(prodrug approach), expensive and prolonged drug development, and burdensome daily multiple 
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doses to patients.43 Thirdly, the most potent analogues identified from pharmacological 
evaluation would be profiled for in vitro metabolic stability. Suboptimal PK parameters which 
may result in drug candidate failure in later clinical development are identified through metabolic 
characterisation.44 
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CHAPTER 3 
SYNTHESIS AND CHARACTERISATION OF TARGET COMPOUNDS 
 
3.1 Rationale for Design of Target Compounds 
Aminomethylthiazoles and their analogues have well documented antimalarial properties as 
outlined in the previous chapter. Thus, the design, synthesis, and pharmacological evaluation of 
more analogues presented in this dissertation are based on the antimalarial properties observed 
initially. The rationale behind the synthesis of more aminomethylthiazole analogues was to 
expand the SAR studies of this class of compounds. In addition, the synthesis of more analogues 
was envisaged to potentially fine-tune the pharmacological and physicochemical properties of 
the lead compound. In this light, the goal was also to identify analogues with comparable or 
superior pharmacological activity and physicochemical properties to the lead compound. 
Identified analogues would then be profiled extensively in future to evaluate if they are devoid of 
the liabilities (hERG and CYPs 1A2 and 2D6 inhibition)1 reported to be associated with the lead 
compound. Figure 3.1 summarises the rationale for the design and synthesis of the analogues. 
 
 
                                 Figure 3.1 Rationale for design of target compounds. 
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Preliminary SAR studies around MMV010539 have previously been reported in the literature 
(Figure 2.5).1 As stated in the previous chapter, these studies have revealed the importance of the 
different substructural motifs, such as aminomethyl, basic side chain, aminomethylthiazole, and 
N-benzylpyrazole groups. Replacement of any of these groups was found generally detrimental 
to potency (Chapter 2. Section 2.3.4)1 
The two target compounds PCM1-006 and PCM1-012 (Figure 3.2) were designed and 
synthesised to obtain analogues in which the thiazole core (2,4-thiazolyl) of MMV010539 is 
replaced by the pyridyl and reversed thiazole (2,5-thiazolyl) moieties. This was done to 
potentially identify other heterocycles with superior or comparable activity to the lead 
compound. Moreover, the design of PCM1-012 sought to understand whether or not the relative 
positions of nitrogen and sulfur atoms on the thiazole ring were important for antiplasmodial 
activity. MMV010539 was re-synthesised in order to compare its activity to the new analogues. 
 
 
            Figure 3.2 Chemical structures of target compounds PCM1-006, PCM1-012, and 
            MMV010539. 
 
In the preliminary SAR1, it was found that replacement of the N-benzylpyrazole moiety with 
other aromatic and heteroaromatic groups resulted in a significant reduction of antiplasmodial 
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activity (Figure 2.5). In this MSc dissertation, we further explored this portion of SAR, i.e. 
substitution of the N-benzylpyrazole moiety with various aromatic and heteroaromatic 
substituents SAR 3 (Figure 3.3). This was done in order to potentially identify other simpler and 
favourable replacements for the N-benzylpyrazole moiety. In this regard, analogues PCM1-031 - 
PCM1-051 were designed and synthesised (Figure 3.3). 
 
 
Figure 3.3 Chemical structures of target compounds PCM1-031 - PCM1-051. 
 
Another important aspect of this MSc study was the exploration of SAR 2, which involved the 
generation of analogues bearing substituents on the aromatic portion of the benzyl group (Figure 
3.4). This SAR exploration was lacking in the preliminary SAR studies reported in literature.1 In 
this benzyl portion of the compound, the effect of electron withdrawing groups (halogens) and an 
alkyl (tert-butyl) group on activity was investigated. The effect of the relative position of the 
halogen group on the benzyl ring on activity was further explored in an attempt to establish if a 
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more favourable position on the ring exists. Target compounds PCM1-056, PCM1-059, PCM1-
066, PCM1-069, and PCM1-073 were thus designed and synthesised (Figure 3.4). 
 
 
               Figure 3.4 Chemical structures of target compounds PCM1-056 - PCM1-089. 
 
In order to establish whether the benzyl methylene (CH2) linker in the lead MMV010539 is 
critical for activity, PCM1-085 (Figure 3.4) was also designed. Finally SAR 4 (Figure 3.4), in 
which the tert-butyl group was replaced by other substituents, was explored in an effort to 
establish if variations at this position are tolerable with respect to activity. This gave rise to 
analogues PCM1-083, PCM1-087, and PCM1-089 with methyl (Me), p-tolyl and hydrogen (H) 
substituents respectively. These analogues were also expected to shed some light on the size of 
substituents tolerable at that position.  
 
3.2 Synthesis and Characterisation of Aminomethylheteroaryl Pyrazole Carboxamides 
      (PCM1-012, PCM1-006 and MMV010539) 
3.2.1 Retrosynthetic Analysis (PCM1-012, PCM1-006 and MMV010539) 
Scheme 3.1 shows the retrosynthetic analysis of target molecules PCM1-012, PCM1-006, and 
MMV010539. For target molecules PCM1-012 and PCM1-006, an amine protection step leads 
to N-boc-protected intermediates PCM1-011 and PCM1-005. A C-N bond disconnection of the 
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boc-protected amine and functional group interconversion (FGI) further breaks down these 
intermediates to nitrile precursors PCM1-009 and PCM1-004. Amide bond dissociation of 
precursors PCM1-009 and PCM1-004 then leads back to appropriate commercially available 
aromatic amino cyano analogues and pyrazole carboxylic acid. 
The retrosynthetic strategy for MMV010539 was somewhat different with the first step 
involving a FGI to an azide precursor PCM1-008, which was obtained via nucleophilic 
substitution of the corresponding chloro intermediate PCM1-007. The chloro intermediate 
PCM1-007 was in turn obtained via amide bond formation between the commercially available 
pyrazole carboxylic acid and the amine hydrochloride salt PCM1-032. Further disconnections of 
C-N and C-S bonds of the amine hydrochloride salt PCM1-032 finally lead to commercially 
available thiourea and 1,3-dichloroacetone. 
 
 
               Scheme 3.1 Retrosynthetic scheme for carboxamides PCM1-012, PCM1-006, and 
               MMV010539 
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3.2.2 Synthesis of Cyanoheteroaryl Pyrazole Carboxamides PCM1-004 and PCM1-009 
Preparation of the cyanoheteroaryl pyrazole carboxamides PCM1-004 and PCM1-009 was 
achieved following a modified literature procedure described by Cabrera Gonzalez et al. 
(Scheme 3.2).1 
 
 
Scheme 3.2 General synthetic approach for cyanoheteroaryl pyrazole carboxamides PCM1-004 
and PCM1-009. Reagents and conditions: (i) appropriate aminonitrile, EDCI, DMAP, CH2Cl2, rt, 4-20 h 
 
These cyano intermediates were synthesised via amidation of the commercially available 
pyrazole carboxylic acid in the presence of an appropriate commercially available amino cyano 
analogue. This was achieved by stirring a mixture of the benzyl pyrazole carboxylic acid and an 
appropriate amino cyano starting material in the presence of 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDCI) hydrochloride and 4-dimethylaminopyridine (DMAP) in dichloromethane 
(DCM). The reaction leading to the formation of PCM1-004 was complete in 20 h while that for 
the formation of PCM1-009 required only 4 h to go to completion. Good yields of 1-benzyl-3-
tert-butyl-N-(6-cyanopyridin-2-yl)-1H-pyrazole-5-carboxamide (PCM1-004) and 1-benzyl-3-
tert-butyl-N-(5-cyanothiazol-2-yl)-1H-pyrazole-5-carboxamide (PCM1-009) were obtained, 
67% and 71% respectively. Confirmation of the structures of these two intermediates was 
achieved using 1H NMR. 
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3.2.2.1 General Reaction Mechanism 
The formation of the amide bond in the reaction of scheme 3.2 proceeds via the mechanism 
outlined below (Scheme 3.3).2-5 Nucleophilic addition of the deprotonated carboxylic acid 
(carboxylate ion) to EDCI forms the O-acylisourea mixed ester making the carbonyl carbon 
more prone to nucleophilic attack. EDCI, therefore, serves as an activating agent for the 
carboxylic acid. Reaction of the amine with the activated intermediate leads to the desired amide 
and a urea by-product. The formation of the stable urea by-product is the driving force for this 
reaction.6 However, a rearrangement of the unstable O-acylisourea mixed ester, via an acetyl 
transfer, to an unreactive N-acylurea often occurs. This side reaction compromises yields during 
amide bond formation.6 Nevertheless, it can be circumvented to a large extent by carrying out the 
coupling reaction in the presence of a nucleophile like DMAP, whose reaction with the reactive 
O-acylisourea mixed ester is faster than the acetyl transfer side reaction. This produces an 
intermediate still reactive enough to react with the amine. 
    
 
Scheme 3.3 Reaction mechanism for amide bond formation 
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3.2.3 Synthesis of Methylcarbamates PCM1-005 and PCM1-011 
The synthesis of N-boc protected intermediates PCM1-005 and PCM1-011 exploited a modified 
literature procedure reported by Caddick et al.7 This involved the catalytic reduction of the cyano 
groups and in situ boc-protection of the resulting primary amines (scheme 3.4). The reaction was 
carried out by adding an excess of sodium borohydride (NaBH4) to a mixture of the nitrile 
compound (PCM1-004 or PCM1-009), di-tert-butyl dicarbonate (Boc2O), and nickel(II) 
chloride (NiCl2) catalyst in methanol at 0 ⁰C. The reactions proceeded at room temperature and 
as indicated by thin layer chromatography (TLC), were complete in 3-12 h. The nickel catalyst 
was sequestered from the reaction mixtures by treatment with excess ethylenediamine. The 
reactions afforded tert-butyl [6-(1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamido)pyridin-2-
yl]methylcarbamate (PCM1-005) and tert-butyl [2-(1-benzyl-3-tert-butyl-1H-pyrazole-5-
carboxamido)thiazol-5-yl]methylcarbamate (PCM1-011) in 45% and 28% yield respectively 
(scheme 3.4). The diagnostic appearance of a peak around δ 4.27 ppm on the 1H NMR spectra 
corresponding to the methylene (CH2) protons of the reduced cyano group confirmed the 
successful reaction. Successful in situ boc-protection of the resulting primary amine was 
confirmed by a 1H NMR signal around δ 1.35 ppm corresponding to 9 protons of the tert-butyl 
group of the boc functionality. 
 
 
Scheme 3.4 General synthetic approach for methylcarbamates PCM1-005 and PCM1-011. 
Reagents and conditions: (ii) Boc2O, NiCl2, NaBH4, 0 ⁰C to rt, 3-12 h, then 1,2-ethylenediamine   
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3.2.3.1 General Reaction Mechanism 
To date, reaction mechanisms involving "transition-metal-assisted" hydride reductions remain 
poorly understood and the nature of the actual reducing species and catalyst generated in situ 
remains a subject of controversy.8 However, a probable mechanism is proposed below (scheme 
3.5) based on the mechanistic studies done on cobalt(II)-mediated reductions by Osby et al.8 
From their findings, they concluded that the cyano group is first activated by complexation to 
cobalt(II) boride (Co2B) surface which is generated in situ. This is followed by the rate 
determining hydride addition to the activated cyano group with dissolved uncoordinated NaBH4 
acting as the donor of hydride ions. Repeated additions of hydride ions lead to the formation of 
the primary amine. Nickel(II) boride (Ni2B) can as well be formed in situ from the reaction of 
NiCl2 and NaBH4 in methanol.
9,10 The Ni2B generated in situ, therefore, acts as a catalytic 
surface in the same fashion Co2B does. The Boc2O present in the reaction mixture serves to 
circumvent the undesirable formation of dimers by reacting with the formed primary amine to 
yield boc-protected analogues.7,11 
 
 
Scheme 3.5 General reaction mechanism for nitrile reduction and N-boc-protection                
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3.2.4 Synthesis of Aminomethylheteroaryl Pyrazole Carboxamides PCM1-006 and  
         PCM1-012  
The final step in the synthesis of carboxamides PCM1-006 and PCM1-012 was a simple 
deprotection of the boc-protected amines to give free amines (Scheme 3.6). With slight 
modifications, the procedure described by Cabrera Gonzalez et al.1 was followed. 
 
 
Scheme 3.6 General synthetic scheme for aminomethylheteroaryl pyrazole carboxamides 
PCM1-006 and PCM1-012. Reagents and conditions: (iii) TFA, CH2Cl2, rt, 15-24 h, then Amberlyst 
A-21, CH2Cl2/CH3OH, 1 h 
  
Excess trifluoroacetic acid (TFA) was added to a solution of the N-boc-protected compound 
(PCM1-005 or PCM1-011) in DCM and reaction mixtures stirred at room temperature for 15-24 
h. Treatment with Amberlyst A-21 weak base ion exchange resin afforded the carboxamides 
PCM1-006 (62% yield) and PCM1-012 (32% yield). With the removal of the boc functionality 
in the deprotection reaction, there was a corresponding disappearance of its 9 proton 1H NMR 
signal. The final target compounds were further characterised by 13C NMR, infrared (IR) 
spectroscopy, mass spectrometry (MS), high performance liquid chromatography (HPLC), TLC, 
and melting point (m.p.) measurements. 
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3.2.4.1 General Reaction Mechanism 
The boc-deprotection reaction mechanism (Scheme 3.7) starts with the protonation of the tert-
butyl carbamate and the subsequent loss of the tert-butyl cation leads to the formation of the 
carbamic acid. The carbamic acid then undergoes decarboxylation to form the amine, which is 
obtained as a salt due to protonation from excess TFA. Deprotonation of the tert-butyl cation 
results in isobutylene gas which escapes from the reaction mixture together with carbon dioxide 
(CO2).
12 The ammonium salt is finally converted to the free amine by the action of Amberlyst A-
21 weak base ion exchange resin. 
 
 
Scheme 3.7 General reaction mechanism for boc-deprotection 
 
3.2.5 Synthesis of Chloromethylthiazole Amine Hydrochloride PCM1-032 
The chloromethylthiazole amine hydrochloride salt PCM1-032 was prepared via a modified 
version of the Hantzsch thiazole synthesis13 detailed by Cabrera Gonzalez et al.1 (Scheme 3.8). 
 
 
Scheme 3.8 Synthetic scheme for chloromethylthiazole amine hydrochloride PCM1-032. 
Reagents and conditions: (iv) CS(NH2)2, acetone, rt, 48 h, then Ethanol, rt, 6 h  
 
The synthesis involved the condensation of 1,3-dichloroacetone and thiourea CS(NH2)2 in 
equimolar amounts to afford PCM1-032 as a white hydrochloride salt in 33% yield. A molecular 
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ion ([M+H]+) peak at mass to charge ratio (m/z) of 149.8571 (C4H6ClN2S requires M 148.9935) 
was observed on the mass spectrum which partly confirmed the identity of this thiazole 
intermediate. 
 
3.2.5.1 Reaction Mechanism 
Formation of the thiazole ring starts with bimolecular nucleophilic substitution (SN2) followed 
by intramolecular nucleophilic addition of the imine nitrogen to the carbonyl carbon (Scheme 
3.9). The resulting hydroxyl intermediate undergoes unimolecular elimination (E1) forming 
chloromethylthiazole amine PCM1-032 as a hydrochloride salt.14,15  
 
 
Scheme 3.9 Reaction mechanism for Hantzsch thiazole formation. 
 
3.2.6 Synthesis of Chloromethylthiazole Pyrazole Carboxamide PCM1-007 
An acid-amine coupling protocol detailed in section 3.2.2 was followed with minor 
modifications. Since the amine in this instance was in the form of a hydrochloride salt (PCM1-
032), it was treated with N,N-diisopropylethylamine (DIPEA) to generate a free basic amine 
before addition to a mixture of pyrazole carboxylic acid, 1-hydroxybenzotriazole (HOBt), and 
EDCI in DCM (Scheme 3.10). HOBt was used in place of DMAP in order to circumvent the 
rearrangement side reaction. The reaction mixture was stirred for 15 h to afford 
chloromethylthiazole pyrazole carboxamide (PCM1-007) in 50% yield. 1H NMR was used to 
confirm the structure of PCM1-007. The reaction proceeds via the same mechanism as detailed 
in section 3.2.2.1. 
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Scheme 3.10 Synthetic scheme to chloromethylthiazole pyrazole carboxamide PCM1-007. 
Reagents and conditions: (v) 4-(chloromethyl)thiazol-2-amine hydrochloride (PCM1-032), N,N-
diisopropylethylamine, EDCI, HOBt, CH2Cl2, 15 h.  
 
3.2.7 Synthesis of Azidomethylthiazole Pyrazole Carboxamide PCM1-008 
Synthesis of the azide intermediate PCM1-008 was accomplished via a simple nucleophilic 
substitution reaction, by stirring a mixture of 1-benzyl-3-tert-butyl-N-(4-(chloromethyl)thiazol-
2-yl)-1H-pyrazole-5-carboxamide PCM1-007 and excess sodium azide (NaN3) in N,N-
dimethylformamide (DMF) solvent at 80 ⁰C for 26 h. This afforded the azide precursor PCM1-
008 in good yield (90%) (Scheme 3.11).1 The azide precursor was subjected to electron 
ionisation mass spectrometry (EI-MS) analysis. A molecular ion at m/z 395.0193 (C19H21N7OS 
requires M 395.1528) was observed. The reaction mechanism for this reaction involves an SN2 
pathway described in section 3.2.5.1.16  
 
 
Scheme 3.11 Synthetic scheme to the azide precursor PCM1-008. Reagents and conditions: (vi) 
NaN3, DMF, 80 ⁰C, 26 h. 
 
3.2.8 Synthesis of Aminomethylthiazole Pyrazole Carboxamide MMV010539 
The final target compound MMV010539, bearing a free primary amine, was synthesised via the 
Staudinger reduction17 of the azide group of precursor PCM1-008. The azide precursor PCM1-
008 was stirred with triphenylphosphine (PPh3) and water in tetrahydrofuran (THF) (Scheme 
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3.12) to furnish the title compound in 68% yield. Characterisation of the target compound was 
performed by 1H NMR, and HPLC. 
 
 
Scheme 3.12 Synthetic scheme to an aminomethylthiazole pyrazole carboxamide MMV010539. 
Reagents and conditions: (vii) H2O, PPh3, THF, rt, 24 h. 
 
3.2.8.1 Reaction Mechanism 
In the first step, the terminal nitrogen of the organic azide is attacked by the nucleophilic 
phosphorous atom of triphenylphosphine (Scheme 3.13). The phosphazide intermediate 
generated undergoes rearrangement to release nitrogen gas and form a N-P ylide, which is 
resonance stabilised. A water molecule then adds to the phosphorous atom. A series of proton 
transfer steps then leads to the formation of the primary amine, along with the 
triphenylphosphine oxide by-product.18  
 
 
Scheme 3.13 Reaction mechanism of Staudinger reduction.17,18 
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Table 1 summarises the final target compounds with their respective percentage yields and 
melting points. Compound MMV010539 was originally synthesised and reported by Cabrera 
Gonzalez et al.1 and, therefore, the literature melting point is recorded. 
 
Table 1. Aminomethylheteroaryl pyrazole carboxamides PCM1-006, PCM1-012 and 
               MMV010539 with their respective yields and melting points. 
 
Ar Code % Yield Mp (⁰C) 
 
 
PCM1-006 
 
62 
 
137-140 
 
 
PCM1-012 
 
32 
 
83-85 
 
 
MMV010539 
 
68 
 
163-165* 
                                                                  *Literature value1 
 
3.3 Synthesis and Characterisation of Aminomethylthiazole Carboxamides (PCM1-031, 
       PCM1-041, PCM1-051, PCM1-083, PCM1-085 and PCM1-087) and 
       Aminomethylthiazole Benzamides (PCM1-034, PCM1-036, PCM1-040 and PCM1-046) 
3.3.1 Retrosynthetic Analysis for Aminomethylthiazole Carboxamides (PCM1-031, PCM1- 
         041, PCM1-051, PCM1-083, PCM1-085 and PCM1-087) and Aminomethylthiazole 
         Benzamides (PCM1-034, PCM1-036, PCM1-040 and PCM1-046) 
A retrosynthetic approach shown in scheme 3.14 was followed to generate the aforementioned 
carboxamides and benzamides. 
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Scheme 3.14 Retrosynthetic approach to carboxamides (PCM1-031, PCM1-041, PCM1-051, 
PCM1-083, PCM1-085 and PCM1-087) and benzamides (PCM1-034, PCM1-036, PCM1-040, 
and PCM1-046). 
 
The retrosynthetic approach (Scheme 3.14) towards the aforementioned benzamides and 
carboxamides indicates an N-boc-protection step and a C-N disconnection to lead back to the 
amino intermediate PCM1-028 and appropriate commercially available carboxylic acids. Further 
analysis suggests N-boc-deprotection to an aminomethylthiazole intermediate PCM1-027. The 
N-boc-protection step is necessary to ensure regioselective amidation of the amino group at 
position 2 of the thiazole intermediate PCM1-027. An FGI step converts the aminomethyl 
functionality of PCM1-027 to the chloromethyl group of the previously synthesised (see section 
3.2.5) starting material PCM1-032. 
 
3.3.2 Synthesis of the Aminothiazole Methylcarbamate PCM1-028  
Aminothiazole methylcarbamate PCM1-028 was synthesised following scheme 3.15 outlined 
below. This involved a nucleophilic substitution followed by the N-boc protection of the 
resulting primary amine PCM1-027. The amine alkylation, or amino-de-halogenation 
(nucleophilic substitution), reaction was carried out following a modified literature procedure 
detailed by Cabrera Gonzalez et al.1 The 4-(chloromethyl)thiazol-2-amine hydrochloride salt 
PCM1-032 was stirred in excess 7 N ammonia in methanol for 72 h at rt. The alkylation of 
ammonia to give primary amines is usually problematic and characterised by poor yields. This is 
due to the primary amine, RNH2, formed being highly nucleophilic and will, therefore, also react 
with the alkyl halide in the reaction mixture, resulting in a mixture containing primary amines, 
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secondary amines, tertiary amines and quaternary ammonium salts. To circumvent the formation 
of other undesirable amines, a large excess of ammonia (33 eq) was used.19a The bright yellow 
solution was concentrated in vacuo to afford 4-(aminomethyl)thiazol-2-amine (PCM1-027) as a 
yellow solid which was used without further purification. The reaction mechanism involved is a 
simple SN2 pathway as discussed in section 3.2.5.1. 
 
 
Scheme 3.15 Synthetic approach to an aminothiazole methylcarbamate PCM1-028. Reagents and 
conditions: (i) methanolic ammonia (7 N), sealed tube, rt, 72 h; (ii) triethylamine, di-tert-butyl 
dicarbonate, 0 ⁰C to rt, 20 h. 
 
Selective N-boc protection of the primary amine was achieved by reacting equimolar amounts of 
Boc2O and 4-(aminomethyl)thiazol-2-amine PCM1-027 in the presence of a slightly excess 
amount of triethylamine (TEA) in DMF (Scheme 3.15). This afforded tert-butyl (2-aminothiazol-
4-yl)methylcarbamate (PCM1-028) as a yellow solid in 32% yield. The appearance of a 1H 
NMR signal around δ 1.43 ppm integrating for the relatively shielded 9 protons confirmed the 
successful incorporation of the boc functionality.  
The reaction proceeds via a nucleophilic addition of the primary amine to Boc2O (see scheme 
3.5). In this specific case, TEA serves to scavenge acid formed after nucleophilic addition.19b 
 
3.3.3 Synthesis of Thiazole Methylcarbamates PCM1-081, PCM1-084, PCM1-086 and 
         PCM1-029 - PCM1-049 
The thiazole methylcarbamates, PCM1-081, PCM1-084, PCM1-086 and PCM1-029 - PCM1-
049 were synthesised via amidation of the appropriate commercially available carboxylic acids 
in the presence of tert-butyl(2-aminothiazol-4-yl)methylcarbamate PCM1-028. The protocol is 
as described in section 3.2.2 with minor modifications in some instances (Scheme 3.16). All the 
acid-amine coupling reactions exploited the presence of EDCI and DMAP and required 3 – 48 h 
to go to completion. Progress of the reactions was monitored by TLC. The crude reaction 
mixtures of intermediates PCM1-029 - PCM1-049 were not subjected to aqueous work up. 
Instead, they were directly concentrated in vacuo and purified by column chromatography. The 
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thiazole methylcarbamate intermediates PCM1-081, PCM1-084, PCM1-086 and PCM1-029 - 
PCM1-049 were obtained in low to excellent yields (32 – 95%).  
 
 
Scheme 3.16 Synthetic approach to thiazole methylcarbamates PCM1-081, PCM1-084, PCM1-
086 and PCM1-029 - PCM1-049. Reagents and conditions: (iii) Appropriate carboxylic acid, EDCI, 
DMAP, CH2Cl2, 3 - 48 h. 
 
During the acid-amine coupling, the carboxylic acid is activated by a nucleophilic reaction with 
EDCI. This is followed by nucleophilic addition of the amine to the activated carboxylic acid-
EDCI adduct to form the amide bond. As described in section 3.2.2.1, DMAP serves to 
circumvent the rearrangement side reaction by forming a carboxylic acid-DMAP adduct which is 
still reactive enough to react with the amine (see section 3.2.2.1 for detailed description of 
reaction mechanism). 
 
3.3.4 Synthesis of Aminomethylthiazole Carboxamides and Aminomethylthiazole 
         Benzamides PCM1-083, PCM1-085, PCM1-087 and PCM1-031-PCM1-051 
The final step in the synthesis of aminomethylthiazole carboxamides and aminomethylthiazole 
benzamides (PCM1-083, PCM1-085, PCM1-087 and PCM1-031-PCM1-051) involved the N-
boc-deprotection reaction using TFA to give the free amines (Scheme 3.17). The procedure 
described in section 3.2.4 was followed to obtain the title compounds in poor to good yields (13 
– 84%). The disappearance of the 1H NMR signal around δ 1.47 ppm integrating for 9 protons of 
the boc group confirmed the successful N-boc-deprotection of the amino functionality. The target 
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compounds were further subjected to 13C NMR, IR, EI-MS, HPLC, TLC, and m.p measurements 
for full characterisation. 
 
 
Scheme 3.17 Synthetic approach to aminomethylthiazole carboxamides and 
aminomethylthiazole benzamides PCM1-083, PCM1-085, PCM1-087 and PCM1-031 - 
PCM1-051. Reagents and conditions: (iii) TFA, CH2Cl2, rt, 4 - 42 h, then Amberlyst A-21, 
CH2Cl2/CH3OH, 1 h. 
 
The isolated yields, melting points, and chemical structures of the aminomethylthiazole 
carboxamides and aminomethylthiazole benzamides PCM1-083, PCM1-085, PCM1-087 and 
PCM1-031 - PCM1-051 are summarised in table 2. 
Table 2. Isolated yields, melting points and chemical structures of analogues PCM1-083, 
               PCM1-085, PCM1-087, and PCM1-031 - PCM1-051. 
    
R Code % Yield Mp (⁰C) 
 
 
PCM1-031 
 
19 
 
174-176 
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PCM1-034 
 
84 
 
214-216 
 
 
PCM1-036 
 
83 
 
213-214 
 
 
PCM1-040 
 
78 
 
182-186 
 
 
PCM1-041 
 
28 
 
151-153 
 
 
PCM1-046 
 
63 
 
209-210 
 
 
PCM1-051 
 
57 
 
176-180 
 
PCM1-083 35 158-160 
 
PCM1-085 54 85-88 
 
PCM1-087 13 85-87 
 
3.4 Synthesis and Characterisation of Aminomethylthiazole Pyrazole Carboxamides 
      (PCM1-056 - PCM1-073 and PCM1-089) 
3.4.1 Retrosynthetic Analysis (PCM1-056 - PCM1-073 and PCM1-089) 
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Aminomethylthiazole pyrazole carboxamides, PCM1-056 - PCM1-073 and PCM1-089 were 
obtained following a retrosynthetic plan shown in scheme 3.18. Protection of the amino group 
yields N-boc-protected intermediates, which upon a C-N disconnection, lead to a variety of 
commercially available benzyl bromides and the basic pyrazole intermediate. A further amide 
disconnection then leads to the crucial amino intermediate PCM1-028, of which the synthesis 
has been discussed (See section 3.3.1), and commercially available pyrazole carboxylic acids. 
Keeping the amine boc-protected in the synthetic steps 1 and 2 is necessary to avoid its coupling 
to the carboxylic acid and N-benzylation respectively. Once steps 1 and 2 are executed, the 
amine could be deprotected to afford the target compounds. 
  
 
Scheme 3.18 Retrosynthetic approach to aminomethylthiazole pyrazole carboxamides, PCM1-
056 - PCM1-073 and PCM1-089 
 
3.4.2 Synthesis of Pyrazole Thiazole Methylcarbamates PCM1-054 and PCM1-082 
The preparation of the pyrazole intermediates PCM1-054 and PCM1-082 exploited an acid-
amine coupling reaction (Scheme 3.19) mediated by EDCI and DMAP as discussed previously 
(see section 3.2.2) albeit minor modifications were made. To obtain the pyrazole intermediate 
PCM1-082, the reaction was carried out in DMF due to the poor solubility of the carboxylic acid 
starting material in DCM. After stirring for 48 h, the PCM1-054 reaction mixture was 
concentrated in vacuo and directly subjected to column chromatography without any aqueous 
work up. This afforded tert-butyl (2-(3-tert-butyl-1H-pyrazole-5-carboxamido)thiazol-4-
yl)methylcarbamate (PCM1-054) as a white solid in 42% yield. The reaction mixture for 
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PCM1-082 was stirred for 20 h, after which water was added to precipitate the product out of 
solution. The resulting precipitate was filtered, sequentially washed with water, hexane, and a 
minimal amount of ethyl acetate to furnish tert-butyl (2-(1H-pyrazole-5-carboxamido)thiazol-4-
yl)methylcarbamate (PCM1-082) as a brown solid in 55% yield. 
 
 
Scheme 3.19 Synthetic approach to pyrazole thiazole methylcarbamates PCM1-054 and PCM1-
082. Reagents and conditions: (iii) Appropriate pyrazole carboxylic acid, EDCI, DMAP, CH2Cl2 
(PCM1-054), DMF (PCM1-082), 20 - 48 h. 
 
The pyrazole intermediates were confirmed by 1H NMR. Additional peaks in the aromatic region 
at approximately δ 7.24 ppm and δ 7.02 ppm, integrating for a proton each, correspond to the 
two CH protons on the pyrazole moiety of PCM1-082. The appearance of an extra peak at δ 6.80 
ppm and δ 1.34 ppm integrating to 1 aromatic CH proton and comparatively shielded 9 tert-butyl 
protons respectively confirmed the successful synthesis of PCM1-054.  
The two coupling reactions proceed via the mechanism outlined in section 3.2.2.1 (see scheme 
3.3). 
 
3.4.3 Synthesis of Benzyl Pyrazole Thiazole Methylcarbamates PCM1-055, PCM1-057 
         PCM1-064, PCM1-067, PCM1-071, and PCM1-088 
The benzyl pyrazole thiazole methylcarbamates PCM1-055, PCM1-057, PCM1-064, PCM1-
067 and PCM1-071 were synthesised via a common pyrazole intermediate PCM1-054. 
Analogue PCM1-088 on the contrary, was synthesised from the pyrazole intermediate PCM1-
082 (Scheme 3.20). 
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Scheme 3.20 Synthetic approach to benzyl pyrazole thiazole methylcarbamates. Reagents and 
conditions: (iii) Appropriate benzyl bromide, K2CO3, DMF or acetonitrile, rt, 21 - 48 h 
 
A protocol described by Andrés et al.20, with a few modifications made in some reactions, was 
followed to carry out benzylation of the NH group of the pyrazole moiety. Analogues PCM1-
055 - PCM1-071 and PCM1-088 were synthesised by respectively benzylating the pyrazoles 
PCM1-054 and PCM1-082 with appropriate benzyl bromides in the presence of potassium 
carbonate (K2CO3) base in DMF or acetonitrile at room temperature. The majority of the 
reactions were performed in DMF due to poor solubility of the starting materials in acetonitrile. 
Analogue PCM1-071 was purified by preparative-TLC after failed column chromatographic 
separation. For analogues PCM1-055 and PCM1-057, acetonitrile was used as the solvent. All 
the analogues were obtained in 26 – 48 % yield and confirmed by 1H NMR. 
 
3.4.3.1 General Reaction Mechanism 
The mechanism for the formation of N-benzylated pyrazoles involves attack of the benzyl carbon 
by the nucleophilic pyrazole nitrogen in an SN2 fashion. K2CO3 base then scavenges the proton 
on the positively charged intermediate (Scheme 3.21).21 
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Scheme 3.21 Reaction mechanism for N-benzylation.21 
 
3.4.4 Synthesis of Aminomethylthiazole Pyrazole Carboxamides PCM1-056 - PCM1-073 
         and PCM1-089 
The aminomethylthiazole pyrazole carboxamides, PCM1-056 - PCM1-073 and PCM1-089 
were obtained from the corresponding benzyl pyrazole thiazole methylcarbamate precursors by 
an N-boc-deprotection reaction (Scheme 3.22) through treatment with TFA, similar to that 
discussed in section 3.2.4. 
 
 
Scheme 3.22 Synthetic scheme to aminomethylthiazole pyrazole carboxamides PCM1-056 - 
PCM1-073 and PCM1-089. Reagents and conditions: (iii) TFA, CH2Cl2, rt, 12 - 72 h, then Amberlyst 
A-21, CH2Cl2/CH3OH, 1 h. 
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The aminomethylthiazole pyrazole carboxamides were obtained in low to moderate yields and 
characterised by 1H NMR, 13C NMR, IR, EI-MS, HPLC, TLC, and melting point measurements. 
1H NMR spectra for all the analogues showed a disappearance of a 9 proton signal around δ 1.45 
ppm that corresponded to the relatively shielded tert-butyl protons of the boc group. This 
confirmed the successful amine-boc-deprotection. 
The final target compounds with their yields and melting points are tabulated below (Table 3) 
Table 3. Isolated yields, melting points and chemical structures of Aminomethylthiazole 
               Pyrazole Carboxamides PCM1-056 - PCM1-073 and PCM1-089. 
 
Product Structure Code % Yield Mp (⁰C) 
 
PCM1-056 22 115-117 
 
PCM1-059 16 92-94 
 
PCM1-066 50 143-145 
 
PCM1-069 68 149-153 
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PCM1-073 52 118-120 
 
PCM1-089 23 166-169 
 
3.5 Characterisation of Target Compounds 
All the resulting analogues displayed a characteristic singlet 1H NMR peak around δ 4 ppm 
integrating for 2 protons. This signal corresponds to the 2 methylene (CH2) protons of the 
aminomethyl motif, which is common in all the final target compounds. Except for PCM1-031 - 
PCM1-051, and PCM1-085 (Table 2), which lacked a benzyl group, a characteristic singlet 1H 
NMR peak around δ 5.8 ppm integrating for 2 benzyl CH2 protons was observed in the 
1H NMR 
spectra of all the final compounds. A common 1H NMR peak at around δ 1.30 ppm integrating 
for 9 protons of the tert-butyl group was also observed for final compounds bearing the tert-butyl 
group on the pyrazole ring. For example MMV010539, PCM1-006, PCM1-012 (Table 1), 
PCM1-056, PCM1-059, PCM1-066, PCM1-069, PCM1-073 (Table 3), and PCM1-085 (Table 
2), exhibited this common 1H NMR peak. A characteristic 13C NMR peak at around δ 39 ppm 
was evident in the 13C NMR spectra of all the final target compounds. This common peak 
corresponds to the aminomethyl methylene (CH2NH2) carbon that is present in all the 
compounds. A relatively shielded benzyl carbon present in analogues PCM1-089, PCM1-073, 
PCM1-069, PCM1-066, PCM1-059, PCM1-056 (Table 3), PCM1-087, PCM1-083 (Table 2), 
MMV010539, PCM1-012, and PCM1-006 (Table 1), gave rise to a 13C NMR peak at around δ 
55 ppm. For all the analogues bearing a tert-butyl group on the pyrazole ring such as  
MMV010539, PCM1-006, PCM1-012 (Table 1), PCM1-056, PCM1-059, PCM1-066, PCM1-
069, PCM1-073 (Table 3), and PCM1-085 (Table 2), a corresponding peak appeared relatively 
upfield at around δ 30 ppm in all their 13C NMR spectra. In addition, a 13C NMR signal at around 
the same chemical shift (δ 30.5 ppm) corresponding to the highly shielded tertiary carbon of the 
tert-butyl group was observed for such compounds. Also notable and common to all 13C NMR 
spectra of all the target compounds was the signal of the carbonyl carbon of the amide bond. 
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This, as expected from the structures of the compounds, was observed relatively downfield at 
approximately δ 160 ppm. This further confirms the authenticity of the target compounds.  
For the aminomethylheteroaryl pyrazole carboxamides PCM1-006, PCM1-012 and 
MMV010539 (Table 1), a representative 1H NMR spectrum for PCM1-012 is shown (Figure 
3.5). A representative 1H NMR spectrum for PCM1-036 (Figure 3.6) from the 
aminomethylthiazole benzamides and aminomethylthiazole carboxamides PCM1-083, PCM1-
085, PCM1-087 and PCM1-031 - PCM1-051 (Table 2) is also shown. The aminomethylthiazole 
pyrazole carboxamides PCM1-056 - PCM1-073 and PCM1-089 of Table 3 are represented by 
the 1H NMR spectrum of PCM1-056 (Figure 3.7). 
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Figure 3.5 1H NMR spectrum of PCM1-012 at 400 MHz in CDCl3. 
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Figure 3.6 1H NMR spectrum of PCM1-036 at 400 MHz in CD3OD. 
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IR analysis of all target compounds revealed common characteristic IR bands at around        
1700 cm-1 and 3400 cm-1 corresponding to the carbonyl (C=O), and primary amine (N-H) 
stretches respectively. A relatively strong absorption band corresponding to a C-H stretch of the 
aminomethyl methylene (CH2) group was as well observed at around 2900 cm
-1 for all the 
analogues. Analogue PCM1-034 (Table 2) notably showed a distinct and sharp absorption band 
at 2228.44 cm-1 corresponding to the cyano (CN) stretch. Other notable functionalities like the 
aromatics also displayed absorption bands at approximately 1550 cm-1 and 3100 cm-1 which 
correspond to aromatic C=C and Ar-H stretches respectively. Mass spectrometry (EI-MS) 
analysis was used to confirm the molecular weights of the target compounds. HPLC was used to 
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Figure 3.7 1H NMR spectrum of PCM1-056 at 400 MHz in CD3OD 
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check the purity of the target compounds. This was to ensure the target compounds had 
acceptable purity (≥ 95%) for biological evaluation.  
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CHAPTER 4 
PHARMACOLOGICAL EVALUATION, SOLUBILITY, AND DISCUSSION 
 
4.1 Chapter Overview 
The pharmacological evaluation and aqueous solubility results of the synthesised target 
compounds are covered in this chapter. A number of analogues of the lead compound 
MMV010539 were synthesised. Some analogues resulted from the changes made on the 
periphery of the lead molecule such us the introduction of substituents on the aromatic portion of 
the benzyl group and replacement of the tert-butyl group with other groups. The SAR, with 
respect to in vitro antiplasmodial activity, resulting from such peripheral modifications is 
discussed. Further drastic modifications to the skeleton of the aforementioned lead molecule 
were made. Such modifications included completely replacing the bulky benzyl pyrazole motif 
with smaller aromatic and heteroaromatic groups. Such a simplification resulted in another set of 
analogues whose SAR data is also discussed. In addition, the chapter discusses the SAR of the 
two analogues derived from replacements of the thiazole core. A more subtle change – 
eliminating the benzylic CH2 in the lead molecule, was made. The importance of such a linker 
with respect to in vitro antiplasmodial activity is also discussed in this chapter. As pointed out 
earlier in section 2.5 of this dissertation, the aqueous solubility of a drug is of paramount 
importance as poor solubility negatively impacts many other properties of the drug such as 
bioavailability, efficacy, and PK profiles.1 This chapter therefore further endeavours to discuss 
the solubility results of the analogues. The in vitro antiplasmodial activity for each compound is 
expressed as an IC50 value which represents a concentration of the test compound which 
produces a 50% inhibition of the parasite growth.2 It is extremely important for drugs to exert 
their therapeutic action at a low concentration to minimise undesirable side effects.3 Therefore, a 
low IC50 value for each analogue was of paramount importance in this project. Unless otherwise 
stated, all the IC50 values are averages of experiments done in triplicate and are presented and 
discussed in µM although corresponding values in µg/mL are also given in brackets in the tables. 
The drug-sensitive strain of P. falciparum, NF54, was employed in all the assays to test the 
compounds for activity. The full details for the biological assays used are presented in the 
experimental section. 
Solubility determination was performed using the turbidimetric (kinetic) method.4 Solubility 
values are classified as follows: < 20 µM = poorly soluble, 20 – 80 µM = moderately soluble, 80 
- 200 µM = good solubility, > 200 µM = highly soluble. 
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4.2 In Vitro Antiplasmodial Activity and Solubility of Aminomethylheteroaryl Pyrazole 
      Carboxamides (PCM1-012, PCM1-006 and MMV010539) 
The lead compound MMV010539 and analogue PCM1-006 were evaluated for in vitro 
antiplasmodial activity in the same assay while a different assay was used for analogue PCM1-
012 albeit the same method was employed. The in vitro antiplasmodial evaluation for these 
compounds and all the others in this MSc dissertation was undertaken at University of Cape 
Town Division of Pharmacology in Professor Peter Smith’s laboratory. The lead compound 
MMV010539 was synthesised and tested for comparison purposes. Chloroquine diphosphate and 
artesunate were used as reference drugs. Aqueous solubility profiling of the compounds was 
performed at pH 7.4 to mimic physiological pH,5 using the turbidimetric assay in which 
hydrocortisone and reserpine served as controls. The in vitro antiplasmodial activity and 
solubility results are tabulated below (Table 4). 
Table 4. In vitro antiplasmodial activity and aqueous solubility for PCM1-006, PCM1-012 and 
               MMV010539 
 
 
Ar Code IC50 µM (µg/mL), NF54 Solubility µM, pH 7.4 
 
 
PCM1-006 
 
0.125 (0.0453) 
 
40 
 
 
PCM1-012 
 
9.09 (0.336)a 
 
80 
 
 
MMV010539 
 
0.0203 (0.0075) 
 
> 200 
_ Chloroquine 0.014 (0.0072)* _ 
_ Artesunate 0.0109 (0.0042)* _ 
*Mean from n = 4 experiments 
aTested in the same assay as analogues of table 5 
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The lead compound MMV010539 exhibited comparable activity (IC50 = 0.0203 µM) to 
chloroquine (IC50 = 0.014 µM) but was relatively less active than artesunate (IC50 = 0.0109 µM). 
Neither of the two analogues, PCM1-006 and PCM1-012, possessed potency comparable or 
superior to that of the lead compound. Although replacement of the thiazole nucleus with the two 
heterocycles reduced the activity, analogue PCM1-006 was the most active of all the analogues 
investigated in this project. PCM1-006 retained sub-µM activity (IC50 = 0.125 µM) and this 
result points to the fact that changes on this portion of the molecule may be the most favourable. 
Noteworthy is the activity of PCM1-012 (IC50 = 9.09 µM) which is significantly lower than that 
of the lead compound MMV010539 (IC50 = 0.0203 µM). A relatively subtle change – 
interchanging the positions of nitrogen and sulfur atoms on the thiazole nucleus, dramatically 
reduces the activity. This change is also equivalent to changing the position of the aminomethyl 
group from 4 to 5. 
The lead compound MMV010539 also possessed higher solubility (> 200 µM) than its 
counterparts PCM1-006 (40 µM) and PCM1-012 (80 µM). The relatively low solubility of 
PCM1-006 compared to MMV010539 and PCM1-012 is expected since its pyridyl core makes 
it more lipophilic and hence less soluble in the aqueous medium at physiological pH. 
MMV010539 and PCM1-012, however, have a more polar thiazole core with twice the number 
of hydrogen bond acceptors (nitrogen and sulfur atoms) as PCM1-006 (nitrogen atom only). The 
relatively low solubility of analogue PCM1-12 (80 µM) compared to MMV010539 (> 200 µM) 
could be due to disruption of the intermolecular interactions that favour maximum solubility in 
the aqueous medium as the nitrogen and sulphur atoms are interchanged. 
 
4.3 In Vitro Antiplasmodial Activity and Solubility of Aminomethylthiazole Carboxamides 
      and Aminomethylthiazole Benzamides (PCM1-031 - PCM1-051) 
Analogues PCM1-031 - PCM1-051 were tested as a single batch with analogue PCM1-012 of 
table 4 in the same assay. This series (PCM1-031 - PCM1-051) of analogues was generated by 
replacement of the benzyl pyrazole moiety of the lead molecule MMV010539 with other simpler 
aromatic and heteroaromatic groups. The in vitro antiplasmodial activity of the lead compound is 
included for comparison purposes. The in vitro antiplasmodial activities and aqueous solubility 
data are summarised in table 5. 
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Table 5. In vitro antiplasmodial activity and aqueous solubility for analogues  
               PCM1-031 - PCM1-051, and MMV010539 
 
R Code IC50 µM (µg/ml), NF54 Solubility µM, pH 7.4 
 
 
 
MMV010539 
 
 
0.0203 (0.0075)a 
 
 
> 200 
 
 
PCM1-031 
 
91.7 (22.0) 
 
80 
 
 
PCM1-034 
 
146 (37.7) 
 
20 
 
 
PCM1-036 
 
40.2 (12.1) 
 
40 
 
 
PCM1-040 
 
43.9 (13.9) 
 
40 
 
 
PCM1-041 
 
149 (35.7) 
 
80 
 
 
PCM1-046 
 
123 (30.9) 
 
80 
 
 
PCM1-051 
 
173 (40.7) 
 
> 200 
_ Chloroquine 0.0119 (0.00613) _ 
_ Artesunate 0.00663 (0.00255)* _ 
*Mean from n = 2 experiments 
aTested in the same assay as analogue PCM1-006 of table 4 
 
From the antiplasmodial activities of all the analogues of this series (PCM1-031 - PCM1-051), 
we can generally conclude that drastic modifications to the skeleton of the lead molecule 
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MMV010539 appears detrimental to potent activity. Activity was on average most negatively 
affected in this series compared to other series of analogues resulting from other modifications 
made around the lead compound. Cabrera Gonzalez et al.6, have reported significant reduction in 
in vitro antiplasmodial activity with the replacement of the benzyl pyrazole motif with other 
aromatic and heteroaromatic substituents. In vitro antiplasmodial activity results for this series of 
compounds PCM1-031 - PCM1-051 is, therefore, not surprising at all. From these findings, it is 
clear that the benzyl pyrazole motif is the most critical portion of the lead molecule. 
With the exception of PCM1-051, all the analogues in this series had moderate to good aqueous 
solubilities (20 - 80 µM), but much lower than that of the lead compound MMV010539 (> 200 
µM). The good solubility of analogue PCM1-051 could be due to the two hydrogen bond 
acceptors (two nitrogen atoms) present in its pyrazinyl moiety. These nitrogen centres could be 
facilitating hydrogen bonding interactions with water in the aqueous medium of the assay and 
hence enhancing its solubility. 
 
4.4 In Vitro Antiplasmodial Activity and Solubility of Aminomethylthiazole Pyrazole 
      Carboxamides (PCM1-056 - PCM1-073 and PCM1-085) 
This series of compounds resulted from much more subtle modifications made to the lead 
compound MMV010539, which included introducing substituents on the aromatic portion of the 
benzyl group as well as replacing the benzyl group with a phenyl ring. All the resulting 
analogues including the lead molecule were evaluated in the same assay and their IC50 and 
solubility values are presented in table 6. The solubility of the lead compound MMV010539 was 
only determined once from the previous experiments and is only listed here for comparison 
purposes. 
 
Table 6. In vitro antiplasmodial activity and aqueous solubility for analogues  
                PCM1-056 - PCM1-073, PCM1-085 and MMV010539 
 
R Code IC50 µM (µg/ml), NF54 Solubility µM, pH 7.4 
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MMV010539 
 
0.0218 (0.00804) 
 
> 200 
 
 
PCM1-056 
 
12.1 (4.88) 
 
> 200 
 
 
PCM1-059 
 
12.8 (5.76) 
 
80 
 
 
PCM1-066 
 
1.84 (0.743) 
 
> 200 
 
 
PCM1-069 
 
4.70 (1.90) 
 
ND* 
 
 
PCM1-073 
 
2.58 (1.10) 
 
10 
 
 
PCM1-085 
 
67.5 (24.0) 
 
160 
_ Chloroquine 0.0106 (0.00548) _ 
_ Artesunate 0.00520 (< 0.002) _ 
*ND = Not determined 
 
A few conclusions can be drawn from the in vitro antiplasmodial data obtained for this limited 
series (PCM1-056 - PCM1-073 and PCM1-085) of analogues. It is clear that generally, the 
modifications resulting in the analogues of this series appear tolerable compared to replacements 
of the benzyl pyrazole motif. Although the introduction of substituents on the aromatic portion of 
the benzyl group (analogues PCM1-056 - PCM1-073), generally reduced the activity (IC50 = 
1.84 – 12.8 µM), it does not however, dramatically reduce it compared to activities of analogues 
resulting from benzyl pyrazole replacements. The lead compound MMV010539 still retained 
superior activity (IC50 = 0.0218 µM) relative to all the analogues. Interestingly, analogue PCM1-
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066 with the chloro substituent in the ortho position of the benzyl ring, had approximately 7 fold 
higher activity (IC50 = 1.84 µM) than its para regioisomer PCM1-056 (IC50 = 12.1 µM). It is 
also noteworthy that, of all the benzyl substituted analogues, PCM1-066 had the highest activity, 
which suggests that substitutions at this position may be much more favourable. Another 
interesting result is the poor activity of analogue PCM1-085 (IC50 = 67.5 µM) in which the 
benzyl group was replaced by a phenyl ring which suggests that the benzyl methylene linker is 
important for activity. 
All the analogues, save for PCM1-073, generally exhibited good to high aqueous solubility (80 - 
> 200 µM) – a result which was generally expected due to the fact that this series of analogues 
resulted from minor peripheral changes to the lead molecule. The poor solubility observed for 
analogue PCM1-073 (10 µM) is not surprising at all since this compound contains the highly 
lipophilic tert-butyl substituent on the benzyl ring. 
 
4.5 In Vitro Antiplasmodial Activity and Solubility of Aminomethylthiazole Pyrazole 
      Carboxamides (PCM1-083, PCM1-087 and PCM1-089) 
The three carboxamides PCM1-083, PCM1-087 and PCM1-089 had methyl, para-tolyl, and 
hydrogen substituents respectively in place of the tert-butyl group on the pyrazole heterocycle 
(Table 7). This was an attempt to identify other favourable groups besides the tert-butyl on this 
position of the pyrazole. The IC50 value of the lead compound MMV010539 and those of the 
control drugs, chloroquine and artesunate, are listed in table 7 for comparison purposes. 
 
Table 7. In vitro antiplasmodial activity and aqueous solubility for analogues PCM1-083, 
               PCM1-087, PCM1-089, and MMV010539 
 
R Code IC50 µM (µg/ml), NF54 Solubility µM, pH 7.4 
 
 
MMV010539 
 
0.0218 (0.00804) 
 
> 200 
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PCM1-083 19.8 (6.47) 160 
 
 
PCM1-087 
 
2.03 (0.818) 
 
40 
 
PCM1-089 43.7 (13.7) > 200 
_ Chloroquine 0.0106 (0.00548) _ 
_ Artesunate 0.00520 (< 0.002) _ 
 
A decrease in activity with decrease in size of the substituent was observed for this small series 
of analogues (Figure 4.1). 
 
 
Figure 4.1 Decrease in activity with size of substituent 
 
It appears, therefore, that although the activity is reduced as the tert-butyl is replaced with the 
groups in figure 4.1, bulky groups are much more tolerated. 
The trend in the aqueous solubility of the three analogues was expected with analogue PCM1-
087 having the lowest solubility (40 µM), probably due to the bulky and lipophilic para-tolyl 
group on its pyrazole carboxylic acid residue. Analogue PCM1-089 possessed the highest 
solubility (> 200 µM) probably due to its relatively less lipophilic nature (absence of an alkyl 
group on pyrazole motif) compared to the lead compound MMV010539 as well as the other two 
analogues PCM1-083 and PCM1-087. The relatively poor solubility of analogues PCM1-087 
and PCM1-083 compared to MMV010539 could also be explained from another perspective. 
Being a bulky group and extending above and below the planar aromatic system of the lead 
compound MMV010539, it (tert-butyl group) disrupts potential pi-pi stacking making the lead 
compound highly soluble. On the other hand, introduction of more confined groups like the 
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para-tolyl and methyl groups on analogues PCM1-087 and PCM1-083 respectively enhance pi-
pi stacking which results in relatively poor solubility of these two analogues. However, this line 
of thought fails to explain the excellent solubility of analogue PCM1-089 which on account of 
maximum pi-pi stacking expected, should be the least soluble. 
 
4.6 Conclusion 
Based on the preliminary SAR exploration executed around MMV010539 by Cabrera Gonzalez 
et al.5, we have successfully further broadened the SAR study around this lead compound. With 
respect to in vitro antiplasmodial activity, all the modifications made thus far resulted in reduced 
activity. For the majority of peripheral modifications on the skeleton of the lead compound such 
as the introduction of substituents on the benzyl ring as well as replacement of the tert-butyl 
group with other groups, activity was reduced but not significantly. This phenomenon is 
reflected in analogues PCM1-056, PCM1-059, PCM1-066, PCM1-069, PCM1-073 (Table 6) 
and PCM1-087 (Table 7) which retained some potency (IC50 = 1.84 – 12.8 µM). The benzylic 
CH2 linker was found to be critically important for potent activity as is reflected in the poor 
activity (IC50 = 67.5 µM) of analogue PCM1-085 (Table 6) in which it is absent. For analogues 
PCM1-083, PCM1-087, and PCM1-089, a positive correlation between the size of the 
substituent and in vitro antiplasmodial activity was observed as pointed out in figure 4.1. 
Replacement of the thiazole core was another portion of SAR that was explored in this MSc 
study. Although SAR investigation into this portion of the molecule was not extensive, it gave 
rise to the most potent analogue PCM1-006 (Table 4) of all the analogues synthesised in this 
study. This pyridyl analogue retained sub-µM activity (IC50 = 0.125 µM) and, therefore, this 
result warrants further extensive SAR investigation into this portion of the molecule. The other 
analogue resulting from this portion of SAR PCM1-012 (IC50 = 9.09 µM) uncovered the 
importance of the position of the aminomethyl group on the thiazole ring. As the aminomethyl 
moiety was shifted from position 4 to 5, activity was reduced approximately 400 fold though not 
completely eliminated. Apart from such thiazole replacements, other more drastic modifications 
to the skeleton of the lead compound MMV010539 were made, which included replacing the 
bulky benzyl pyrazole moiety with other smaller and simpler aromatic/heteroaromatic groups 
(PCM1-031 – PCM1-051) (Table 5). With such drastic modifications, activity was 
compromised the most and was significantly reduced in the majority of the resulting analogues 
(IC50 = 40.2 - 173 µM). The benzyl pyrazole motif, therefore, seems critical for activity and as 
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such, drastic modifications on this portion of the molecule should perhaps be avoided in future 
SAR explorations. 
All the synthesised compounds were obtained in poor to good yields (13 – 84%). The poor yields 
of some analogues could be attributed to the difficulty associated with their isolation. For 
instance, chromatographic separation was particularly challenging for some complex crude 
mixtures. 
 
4.7 Recommendations for Future Work 
Further work recommended based on results obtained in this study is summarised in Figure 4.2. 
In light of retention of sub-µM activity (IC50 = 0.125 µM) of the pyridyl analogue PCM1-006 
(Table 4), there is need to generate more analogues with other aromatic heterocycles for more 
extensive investigation into SAR 1. We further found out that analogues resulting from 
replacement of the benzyl pyrazole motif on average had the poorest activity (IC50 = 40.2 - 173 
µM) (Table 5). Future SAR 3 refinements on this portion of the lead compound, should, perhaps, 
focus on making more subtle modifications rather than drastic replacements of the benzyl 
pyrazole moiety. The poor activity (IC50 = 67.5 µM) of analogue PCM1-085 (Table 6) 
highlighted the importance of the benzyl methylene (CH2) linker. However, further SAR 5 
investigations with respect to variations in the length of this linker (i.e. replacement with (CH2)n, 
n > 1) is necessary. Such a drug extension strategy would reveal which linker length is associated 
with optimal pharmacological activity and/or physicochemical parameters. Furthermore, 
additional analogues with other alkyl substituents (propyl, isopropyl, cyclopropyl cyclohexyl and 
others) replacing the tert-butyl group (SAR 4), need investigation. Finally, there is need to 
further replace the benzyl ring of the benzyl group with other five and six membered aromatic 
heterocycles (SAR 2) to potentially identify other groups which can be tolerated. 
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 Figure 4.2 Recommendations for future work 
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CHAPTER 5 
EXPERIMENTAL 
 
5.1 General Comments on Experimental Data 
Solvents used for the majority of experiments were generally distilled and analytical reagent 
(AR) grade in some cases, with the exception of methanol (CH3OH) and absolute ethanol 
(CH3CH2OH) which were exclusively AR grade. Dimethyl sulfoxide (DMSO) used in solubility 
assays was HPLC grade while N,N-dimethylformamide (DMF) used in reactions was anhydrous 
and AR grade. Unless otherwise stated, all the other reagents and starting materials were 
obtained commercially and used without further purification. Analytical thin layer 
chromatographic plates (Merck TLC Silica gel 60 F254 coated on aluminium sheets) were used to 
monitor reaction progress and visualised under ultraviolet (UV 254 and 366 nm) light and in 
cases of final amine compounds, with ninhydrin (2,2-dihydroxyindane-1,3-dione) spray. In 
column chromatographic separations, both on the Biotage isolera one automated flush machine, 
and manual glass tube columns, silica gel (Fluka high purity grade, pore size 60 Å, 70 – 230 
mesh, 63 – 200 µm) was used. 
1H NMR and 13C NMR experiments were performed on either a Bruker AV 400 (1H 400.0, 13C 
100.6 MHz) or Varian Mercury 300 (1H 300.1, 13C 75.5 MHz) instrument housed in the 
Department of Chemistry University of Cape Town. All the spectra were acquired at room 
temperature. Deuterated solvents (CDCl3, CD3OD, and [D6]DMSO) were used as solvents both 
for 1H NMR and 13C NMR experiments. Chemical shifts are reported from low field to high field 
in parts per million (ppm). Multiplicity in all the spectra is expressed using the following 
abbreviations: br s = broad singlet, d = doublet, t = triplet, q = quartet, m = multiplet. Coupling 
constants, J values, are given in Hz. Mass spectra were recorded on a JEOL GCmateII mass 
spectrometer under direct probe conditions and electron impact (EI) ionisation in the positive 
ionisation mode. Infrared (IR) absorption measurements were carried out on the PerkinElmer 
Spectrum 100 FT-IR Spectrometer in the wave number range 450 – 4000 cm-1. All the samples 
were mixed and homogenised with potassium bromide (KBr) and analysed as circular pellets. 
Melting point measurements were done on a Reichert-Jung Thermovar hot stage microscope and 
are not corrected. Purity of the compounds was determined using HPLC and all the compounds 
were found to have acceptable purity (> 95%). 
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Compounds PCM1-069 and PCM1-089 (Sub-section 5.24 of experimental section) are lacking 
13C NMR and IR data respectively due to insufficient material to undertake such analyses. 
 
5.2 General procedure for the synthesis of cyanoheteroaryl pyrazole carboxamides 
      (PCM1-004 and PCM1-009) 
EDCI (2.0 eq) was added to a solution of 1-benzyl-3-(tert-butyl)-1H-pyrazole-5-carboxylic acid 
(1.0 eq) and DMAP (2.0 eq) in dichloromethane. The reaction mixture was stirred for 10 - 15 
minutes, after which the appropriate amino cyano analogue (1.2 eq) was added. The resulting 
reaction mixture was stirred for 4 - 20 h before being washed with saturated aqueous solutions of 
NaHCO3 (3 ×), NH4Cl (2 ×), and NaCl (2 ×). The organic layer was dried (MgSO4), filtered and 
concentrated in vacuo. The crude mixture was chromatographed (SiO2, EtOAc-hexane, 10:90) to 
give the desired nitrile compound. 
 
 
1-Benzyl-3-tert-butyl-N-(6-cyanopyridin-2-yl)-1H-pyrazole-5-carboxamide (PCM1-004) 
White solid (0.4700 g, 67%), δH (400 MHz; CDCl3) 8.83 (1H, br s, H10), 8.40 (1H, d, J = 8.3 Hz, 
H3), 7.93 (1H, t, J = 7.9 Hz, H2), 7.33 (1H, d, J = 7.9 Hz, H1), 7.28-7.03 (5H, m, H6, H7, H8), 6.55 
(1H, s, H4), 5.62 (2H, s, H5), 1.27 (9H, s, H9). 
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1-Benzyl-3-tert-butyl-N-(5-cyanothiazol-2-yl)-1H-pyrazole-5-carboxamide (PCM1-009) 
White solid (0.4018 g, 71%), δH (400 MHz; CDCl3) 10.27 (1H, br s, H2), 7.88 (1H, s, H1), 7.35-
7.20 (5H, m, H5, H6, H7), 6.66 (1H, s, H3), 5.78 (2H, s, H8), 1.34 (9H, s, H4). 
 
5.3 General procedure for the synthesis of benzyl pyrazole methylcarbamates  
      (PCM1-005 and PCM1-011) 
Boc2O (2.0 eq) and NiCl2 (1.0 eq) were added to a solution of the nitrile compound (PCM1-004 
or PCM1-009) (1.0 eq) in methanol and the mixture was cooled to 0 ⁰C. NaBH4 (12.0 eq) was 
added in small portions over approximately 1 h, where after the reaction mixture was warmed to 
room temperature and stirred for 3 - 12 h. Ethylenediamine (20.0 eq) was added and reaction 
mixture stirred for 30 min before the solvent was removed in vacuo. The resulting pink residue 
was taken up in EtOAc and washed with saturated aqueous solution of NaHCO3 (3 ×). The 
organic layer was dried (MgSO4), filtered, concentrated in vacuo and the crude product purified 
by column chromatography (SiO2, 10 – 15% EtOAc/Hexane) to give the N-Boc protected 
intermediates PCM1-005 and PCM1-011. 
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tert-Butyl (6-(1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamido)pyridin-2- 
yl)methylcarbamate (PCM1-005) 
White solid (0.1200 g, 45%), δH (400 MHz; CDCl3) 8.18 (1H, br s, H7), 8.04 (1H,  d, J = 8.2, 
H8), 7.61 (1H, t, J = 7.9, H9), 7.26-7.11 (5H, m, H4, H5, H6), 6.94 (1H, d, J = 7.4, H10), 6.57 (1H, 
s, H1), 5.70 (2H, s, H3,), 4.43 (1H, br s, H12), 4.27 (2H, s, H11), 1.40 (9H, s, H13), 1.29 (9H, s, H2). 
 
 
tert-Butyl (2-(1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamido)thiazol-5- 
yl)methylcarbamate (PCM1-011) 
White solid (0.0183 g, 28%), δH (400 MHz; CDCl3) 7.24-7.10 (5H, m, H5, H6, H7), 7.00 (1H,  s, 
H1), 6.64 (1H, s, H3), 5.71 (2H, s, H8,), 4.76 (1H, br s, H10), 4.31 (2H, s, H9), 1.38 (9H, s, H11,), 
1.24 (9H, s, H4). 
 
5.4 General procedure for the synthesis of aminomethylheteroaryl pyrazole carboxamides 
      (PCM1-006 and PCM1-012) 
TFA (10.0 eq) was added to a stirred solution of N-Boc protected intermediate (PCM1-005 or 
PCM1-011) (1.0 eq) in dichloromethane. The reaction mixture was stirred at room temperature 
for 15 - 24 h and concentrated in vacuo. The remaining residue was dissolved in 10% 
CH3OH/DCM and Amberlyst A-21 weak base ion exchange resin was added where after mixture 
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was left to stir. After stirring for 1.5 h, the mixture was filtered and the Amberlyst washed with 
50% CH3OH/DCM. The filtrate was concentrated in vacuo and the resulting crude mixture 
further purified by column chromatography (SiO2, CH3OH-DCM, 5:95) to deliver the 
carboxamides PCM1-006 and PCM1-012. 
 
 
N-(6-(Aminomethyl)pyridin-2-yl)-1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamide 
(PCM1-006) 
Brown solid (0.0200 g, 62%), m.p. 137-140 ⁰C; Rf  (CH3OH-CH2Cl2 1:9) 0.5; IR vmax(KBr)/cm
-1 
3323 (N-H, 1⁰ amine), 2959 (C-H, tert-butyl CH3), 1682 (C=O, amide), 1583 (C=C, aromatic); 
δH (400 MHz; CDCl3) 8.25 (1H, br s, H12), 8.03 (1H, d, J = 8.3 Hz, H5), 7.59 (1H, t, J = 7.9 Hz, 
H4), 7.23-7.12 (5H, m, H9, H10, H11), 6.93 (1H, d, J = 7.9 Hz, H3), 6.60 (1H, s, H6), 5.72 (2H, s, 
H8), 3.85 (2H, s, H2), 1.56 (2H, br s, H1), 1.28 (9H, s, H7); δC (CDCl3) 161.0, 159.1, 151.0, 151.1, 
139.9 (2C), 138.0, 134.0, 128.4 (2C), 127.6 (2C), 117.2, 114.8, 105.3, 54.9, 44.5, 32.0, 30.5 (3C) 
; EI-m/z found 363.1597 (100%, M+), (C21H25N5O requires M 363.2059); HPLC purity: 98%   (tr 
= 13.3 min). 
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N-(5-(Aminomethyl)thiazol-2-yl)-1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamide (PCM1-
012) 
Brown solid (0.1100 g, 32%), m.p. 83-85 ⁰C; Rf  (CH3OH-CH2Cl2 1.5 : 8.5) 0.5; IR 
vmax(KBr)/cm
-1 3366 (N-H, 1⁰ amine), 2966 (C-H, tert-butyl CH3), 2918 (C-H, aminomethyl 
CH2), 1673 (C=O, amide), 1558 (C=C, aromatic); δH (400 MHz; CDCl3) 7.22-7.11 (5H, m, H6, 
H7, H8), 6.96 (1H, s, H1), 6.64 (1H, s, H4), 5.71 (2H, s, H9), 3.91 (2H, s, H2), 1.24 (9H, s, H5); δC 
(CDCl3) 161.0, 158.1, 157.5, 137.5, 133.5 (2C), 129.1, 128.4 (2C), 127.5 (2C), 105.5, 54.6, 38.5, 
30.4 (3C), 29.9; EI-m/z found 368.9970 (56.6%, M+), (C19H23N5OS requires M 369.1623); 
HPLC purity: 99%   (tr = 13.2 min). 
 
 
5.5 Synthesis of 4-(chloromethyl)thiazol-2-amine hydrochloride (PCM1-032) 
A solution of thiourea (2.59 g, 34.0 mmol) in acetone (80 mL) was added drop wise to a solution 
of 1, 3-dichloroacetone (4.24 g, 33.4 mmol) in acetone (16 mL). The reaction mixture was stirred 
at room temperature for 48 h before being concentrated in vacuo.  Absolute ethanol (32 mL) was 
added to the resulting residue and left to stir at room temperature for 6 h. The white precipitate 
that formed was removed by filtration. The filtrate was then concentrated in vacuo and the 
residue was washed with dichloromethane to afford PCM1-032 as a white hydrochloride salt 
(2.06 g, 33%), EI-m/z found 149.8571(13.4%, M+), (C4H6ClN2S requires M 148.9935). 
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5.6 Synthesis of 1-benzyl-3-tert-butyl-N-(4-(chloromethyl)thiazol-2-yl)-1H-pyrazole-5 
      carboxamide (PCM1-007) 
EDCI (4.66 g, 24.31 mmol) was added to a solution of 1-benzyl-3-(tert-butyl)-1H-pyrazole-5-
carboxylic acid (4.61 g, 17.83 mmol) and hydroxybenzotriazole (HOBt) (3.29 g, 24.31 mmol) in 
dichloromethane (20 mL). After stirring the reaction mixture for 45 min, a solution of 4-
(chloromethyl)thiazol-2-amine hydrochloride (PCM1-032) (3.00 g, 16.21 mmol) and N,N-
diisopropylethylamine (DIEA) (5.65 mL, 32.42 mmol) in dichloromethane (4 mL) was added in 
small portions. The reaction mixture was stirred for 15 h before being washed with saturated 
aqueous solutions of NaHCO3 (4 × 50 mL), NH4Cl (2 × 50 mL), and NaCl (2 × 50 mL). The 
organic layer was dried (MgSO4), filtered, concentrated in vacuo and purified by column 
chromatography (SiO2, EtOAc-hexane, 10:90) to give the intermediate chloro compound PCM1-
007 (3.15 g, 50%) as a white solid, δH (400 MHz; CDCl3) 9.96 (1H, br s, H9), 7.26-7.13 (5H, m, 
H5, H6, H7), 6.90 (1H, s, H1), 6.47 (1H, s, H3), 5.72 (2H, s, H8), 4.34 (2H, s, H2), 1.24 (9H, s, H4). 
 
 
5.7 Synthesis of N-(4-(aminomethyl)thiazol-2-yl)-1-benzyl-3-tert-butyl-1H-pyrazole-5- 
      carboxamide (MMV010539) 
NaN3 (0.33 g, 5.14 mmol) was slowly added to a solution of 1-benzyl-3-tert-butyl-N-(4-
(chloromethyl)thiazol-2-yl)-1H-pyrazole-5-carboxamide PCM1-007 (0.10 g, 0.26 mmol) in 
DMF (1 mL) and reaction mixture stirred at 80 ⁰C for 26 h before being concentrated in vacuo. 
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The resulting residue was taken up in dichloromethane and washed with deionised water (10 
mL). The organic layer was dried (MgSO4), filtered, concentrated in vacuo, and purified by 
column chromatography (SiO2, EtOAc-hexane, 30:70) to afford the azide substituted compound 
PCM1-008 which was confirmed by EI-MS, EI-m/z found 395.0193(52.9%, M+), (C19H21N7OS 
requires M 395.1528). To reduce the azide intermediate to the corresponding amine, water 
(0.0024 g, 0.13 mmol) and triphenylphosphine (0.05 g, 0.20 mmol) were added to a solution of  
N-(4-(azidomethyl)thiazol-2-yl)-1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxamide PCM1-008 
(0.05 g, 0.13 mmol) in THF (2 mL). The reaction mixture was stirred for 24 h before being 
concentrated under reduced pressure. The remaining residue was dissolved in dichloromethane 
(6 mL), washed with deionised water (5 mL), dried (MgSO4), filtered and concentrated in vacuo. 
Purification by column chromatography (SiO2, CH3OH-CH2Cl2, 5:95) afforded MMV010539 
(0.0337 g, 68%) as a white solid,  δH (300 MHz; CDCl3) 7.31-7.17 (5H, m, H6, H7, H8), 6.67 (1H, 
s, H1), 6.65 (1H, s, H4), 5.80 (2H, s, H9), 3.75 (2H, s, H2), 1.32 (9H, s, H5); EI-m/z found 
369.1398(64.1%, M+), (C19H23N5OS requires M 369.1623); HPLC purity: 99.9%   (tr = 13.2 min). 
 
 
5.8 Synthesis of 4-(aminomethyl)thiazol-2-amine (PCM1-027) 
Ammonia solution in methanol (7N) (54 mL, 378 mmol) was added to 4-(chloromethyl)thiazol-
2-amine hydrochloride PCM1-032 (2.06 g, 11.20 mmol) and the reaction mixture stirred in a 
sealed tube at room temperature. After stirring for 72 h, the reaction mixture was concentrated in 
vacuo to afford intermediate PCM1-027 as a yellow solid which was used without further 
purification. 
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5.9 Synthesis of tert-butyl (2-aminothiazol-4-yl)methylcarbamate (PCM1-028) 
Boc2O (2.13 g, 9.80 mmol) was added in small portions to a suspension of 4-
(aminomethyl)thiazol-2-amine PCM1-027 (1.26 g, 9.80 mmol) and triethylamine (4.0 mL, 29 
mmol) in DMF (30 mL) at 0 ⁰C. The reaction mixture was left to warm to room temperature and 
stirred for 24 h. Cold deionised water (25 mL) at 0 ⁰C was added and the mixture extracted with 
ethyl acetate (4 × 85 mL). The combined organic layers were washed with deionised water (4 × 
170 mL), and saturated aqueous NaCl (85 mL), dried (NaSO4), filtered and concentrated in 
vacuo. Purification by column chromatography (SiO2, 0-60% EtOAc/Hexane) furnished PCM1-
028 (0.72 g, 32%) as a yellowish solid, δH (400 MHz; CDCl3) 6.29 (1H, s, H1), 5.16 (1H, br s, 
H3), 4.14 (2H, br s, H5), 3.73 (2H, s, H2), 1.43 (9H, s, H4). 
 
5.10 General procedure for the synthesis of thiazole methylcarbamates (PCM1-081,  
        PCM1-084, PCM1-086 and PCM1-029 - PCM1-049) 
The synthesis of the thiazole methylcarbamates PCM1-081, PCM1-084, PCM1-086 and 
PCM1-029 - PCM1-049 was achieved by following a protocol already described in sub-section 
5.2 of the experimental section. The synthesis basically involved coupling many carboxylic acid 
derivatives to a common amino intermediate PCM1-028 in presence of EDCI and DMAP to 
afford the appropriate thiazole methylcarbamates. However, reaction mixtures for analogues 
PCM1-029 - PCM1-049, were not subjected to aqueous work up procedures but were directly 
chromatographed to give the title compounds. The remaining analogues were otherwise 
subjected to aqueous work up before further purification by column chromatography as 
described in section 5.2.  
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tert-Butyl (2-(thiophene-2-carboxamido)thiazol-4-yl)methylcarbamate (PCM1-029) 
White solid (0.07 g, 93%), δH (400 MHz; CDCl3) 9.16 (1H, br s, H8,), 8.24 (1H,  d, J = 3.7 Hz, 
H4), 7.53 (1H, d, J = 4.9 Hz, H6), 6.91 (1H, t, J = 6.9 Hz, H5), 6.70 (1H, s, H1), 4.14 (2H, d, J = 
6.6 Hz, H2), 1.47 (9H, s, H9). 
 
 
tert-Butyl (2-(4-cyanobenzamido)thiazol-4-yl)methylcarbamate (PCM1-033) 
Brown solid (0.2491 g, 94%), δH (400 MHz; CDCl3) 8.17 (2H, d, J = 8.7 Hz, H4), 7.78 (2H, d, J 
= 8.7 Hz, H5), 6.96 (1H, s, H1), 4.98 (1H, br s, H6), 4.23 (2H, s, H2), 1.45 (9H, s, H3). 
 
 
tert-Butyl (2-(4-(trifluoromethyl)benzamido)thiazol-4-yl)methylcarbamate (PCM1-035) 
White solid (0.2477 g, 78%), δH (400 MHz; CDCl3) 8.17 (2H, d, J = 8.3 Hz, H5), 7.86 (2H, d, J 
= 8.2 Hz, H4), 7.16 (1H, s, H1), 4.98 (1H, br s, H6), 4.13 (2H, s, H2), 1.47 (9H, s, H3). 
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tert-Butyl (2-(thiazole-4-carboxamido)thiazol-4-yl)methylcarbamate (PCM1-038) 
White solid (0.2234 g, 94%), δH (400 MHz; CDCl3) 9.12 (1H, s, H4), 8.48 (1H, s, H5), 7.06 (1H, 
s, H1), 4.98 (1H, br s, H6), 4.14 (2H, s, H2), 1.45 (1H, s, H3). 
 
 
tert-Butyl (2-(4-(trifluoromethoxy)benzamido)thiazol-4-yl)methylcarbamate (PCM1-039) 
White solid (0.1722 g, 55%), δH (400 MHz; CDCl3), 8.20 (2H, d, J = 8.4 Hz, H4), 7.19 (2H, d, J 
= 7.5 Hz, H5), 6.74 (1H, s, H1), 4.95 (1H, t, J = 6.7 Hz, H6), 4.15 (2H, d, J = 6.8 Hz, H2), 1.44 
(9H, s, H3). 
 
 
tert-Butyl (2-(4-fluorobenzamido)thiazol-4-yl)methylcarbamate (PCM1-044) 
White solid (0.1555 g, 68%), δH (400 MHz; CDCl3), 8.26 (2H, m, H4), 7.10 (2H, t, J = 8.6 Hz, 
H5), 6.79 (1H, s, H1), 4.94 (1H, t, J = 8.0 Hz, H6), 4.22 (2H, d, J = 8.0 Hz, H2), 1.49 (9H, s, H3). 
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tert-Butyl (2-(pyrazine-2-carboxamido)thiazol-4-yl)methylcarbamate (PCM1-049) 
Yellow solid (0.2040 g, 98%), δH (400 MHz; CDCl3) 10.78 (1H, br s, H8), 9.44 (1H, s, H6), 8.79 
(1H, s, H5), 8.56 (1H, s, H4), 6.80 (1H, s, H1), 4.99 (1H, br s, H7), 4.29 (2H, s, H2), 1.38 (9H, s, 
H3). 
 
 
tert-Butyl (2-(1-benzyl-3-methyl-1H-pyrazole-5-carboxamido)thiazol-4-yl)methylcarbamate  
(PCM1-081) 
White solid (0.3049 g, 82%) , δH (400 MHz; CDCl3) 12.47 (1H, br s, H10), 8.98 (1H, br s, H11), 
7.34-7.16 (6H, m, H1, H6, H7, H8), 6.76 (1H, s, H4), 5.80 (2H, s, H9), 4.18 (2H, s, H2), 2.27 (3H, s, 
H5), 1.53 (9H, s, H3). 
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tert-Butyl (2-(3-tert-butyl-1-phenyl-1H-pyrazole-5-carboxamido)thiazol-4- 
yl)methylcarbamate (PCM1-084) 
Colourless oil (0.3474 g, 88%), δH (400 MHz; CDCl3) 7.56-7.46 (3H, m, H7, H8), 7.37 (2H, d, J 
= 8.1 Hz, H6), 6.84 (1H, s, H1), 6.69 (1H, s, H4), 5.11 (1H, br s, H9), 4.26 (2H, d, J = 5.2 Hz, H2), 
1.42 (9H, s, H3), 1.20 (9H, s, H5). 
 
 
tert-Butyl (2-(1-benzyl-3-p-tolyl-1H-pyrazole-5-carboxamido)thiazol-4-yl)methylcarbamate 
(PCM1-086) 
White solid (0.1417 g, 88%), δH (400 MHz; CDCl3) 9.09 (1H, br s, H13), 7.73 (2H, d, J = 7.9 Hz, 
H5), 7.64 (1H, s, H1), 7.40-7.11 (7H, m, H6, H8, H9, H10), 6.78 (1H, s, H4), 5.91 (2H, s, H11), 5.08 
(1H, br s, H12), 4.20 (2H, s, H2), 2.37 (3H, s, H7), 1.52 (9H, s, H3). 
 
5.11 General synthetic procedure for the aminomethylthiazole carboxamides and 
         aminomethylthiazole benzamides (PCM1-083, PCM1-085, PCM1-087 and PCM1-031- 
         PCM1-051) 
The final target compounds PCM1-083, PCM1-085, PCM1-087 and PCM1-031-PCM1-051 
were finally obtained by an N-boc-deprotection step using TFA. A generic procedure described 
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under section 5.4 of this dissertation was followed and the title compounds were obtained in poor 
to good yields (13 – 84%). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)thiophene-2-carboxamide (PCM1-031) 
White solid (0.0095 g, 19%), m.p. 174-176 ⁰C; Rf  (CH3OH-CH2Cl2 1.5 : 8.5) 0.14; IR 
vmax(KBr)/cm
-1 3405 (N-H, 1⁰ amine), 2922 (C-H, aminomethyl CH2), 1690 (C=O, amide), 1551 
(C=C, aromatic); δH (400 MHz; CD3OD) 7.93 (1H, s, H3), 7.80 (1H, s, H5), 7.21 (1H, s, H4), 7.06 
(1H, s, H1), 4.02 (2H, s, H2), δC (CD3OD) 179.2, 159.9, 147.3, 144.5, 133.1, 130.2, 128.5, 112.1, 
39.8; EI-m/z found 238.9879 (26.9%, M+), (C10H10N3OS requires M 239.0187); HPLC purity: 
99.4%   (tr = 7.6 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-4-cyanobenzamide (PCM1-034) 
Yellow solid (0.15 g, 84%); m.p. 214-216 ⁰C; Rf  (CH3OH-CH2Cl2 1.5 : 8.5) 0.24; IR 
vmax(KBr)/cm
-1 3418 (N-H, 1⁰ amine), 2922 (C-H, aminomethyl CH2), 2228 (CN, cyano), 1697 
(C=O, amide), 1551 (C=C, aromatic); δH (400 MHz; CD3OD) 8.16 (2H, d, J = 8.3 Hz,  H3), 7.88 
(2H, d, J = 8.1 Hz, H4), 7.08 (1H, s, H1), 4.03 (2H, s, H2); δC (CD3OD) 165.4, 161.3, 145.8, 
137.5, 132.2(3C), 128.4(2C), 117.6, 110.8, 39.6; EI-m/z found 258.0575 (43.2%, M+), 
(C12H10N3OS requires M 258.0575); HPLC purity: 97.6%   (tr = 8.1 min). 
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N-(4-(Aminomethyl)thiazol-2-yl)-4-(trifluoromethyl)benzamide (PCM1-036) 
White solid (0.15 g, 83%);  m.p. 213-214 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.10; IR 
vmax(KBr)/cm
-1 3426 (N-H, 1⁰ amine), 2918 (C-H, aminomethyl CH2), 1694 (C=O, amide), 1551 
(C=C, aromatic) ; δH (400 MHz; CD3OD) 8.17 (2H, d, J = 8.1 Hz,  H3), 7.87 (2H, d, J = 8.2 Hz, 
H4), 7.18 (1H, s, H1), 4.12 (2H, s, H2); δC (CD3OD) 169.5, 159.1, 143.5, 136.0, 133.5, 128.3(3C), 
126.0(2C), 112.5, 38.7; EI-m/z found 301.0507 (30.8%, M+), (C12H10F3N3OS requires M 
301.0497); HPLC purity: 99.9%  (tr = 11.4 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-4-(trifluoromethoxy)benzamide (PCM1-040) 
Brown solid (0.0395 g, 78%);  m.p. 182-186 ⁰C; Rf  (CH3OH-CH2Cl2 1.5:8.5) 0.10; IR 
vmax(KBr)/cm
-1 3426 (N-H, 1⁰ amine), 2922 (C-H, aminomethyl CH2), 1690 (C=O, amide), 1555 
(C=C, aromatic); δH (400 MHz; CD3OD) 8.7 (2H, d, J = 8.7 Hz,  H3), 7.45 (2H, d, J = 8.5 Hz, 
H4), 7.08 (1H, s, H1), 4.02 (2H, s, H2); δC (CD3OD) 165.0, 160.0, 153.0, 144.5, 131.5, 129.8(3C), 
120.6(2C), 111.0, 39.1; EI-m/z found 317.0639 (29.2%, M+), (C12H10F3N3O2S requires M 
317.0446); HPLC purity: 95.2% (tr = 11.8 min). 
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N-(4-(Aminomethyl)thiazol-2-yl)thiazole-4-carboxamide (PCM1-041) 
Brown solid (0.044 g, 28%);  m.p. 151-153 ⁰C; Rf  (CH3OH-CH2Cl2 1.5 : 8.5) 0.20; IR 
vmax(KBr)/cm
-1 3405 (N-H, 1⁰ amine), 2922 (C-H, aminomethyl CH2), 1677 (C=O, amide), 1551 
(C=C, aromatic) ; δH (400 MHz; CD3OD) 9.11 (1H, s,  H3), 8.49 (1H, s, H4), 7.07 (1H, s, H1), 
4.01 (2H, s, H2); δC (CD3OD) 159.1(2C), 154.8, 149.0, 146.5, 125.7, 110.7, 39.8; EI-m/z found 
240.0140 (62.5%, M+), (C8H8N4OS2 requires M 240.0140); HPLC purity: 99.9% (tr = 3.7 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-4-fluorobenzamide (PCM1-046) 
Brown solid (0.0702 g, 63%);  m.p. 209-210 ⁰C; Rf  (CH3OH-CH2Cl2 1.5 : 8.5) 0.10; IR 
vmax(KBr)/cm
-1 3418 (N-H, 1⁰ amine), 2924 (C-H, aminomethyl CH2), 1671 (C=O, amide), 1542 
(C=C, aromatic); δH (400 MHz; CD3OD) 8.07 (2H, dd, J = 5.0, 8.7 Hz,  H3), 7.29 (2H, t, J = 8.7 
Hz, H4), 7.17 (1H, s, H1), 4.13 (2H, s, H2); δC (CD3OD) 167.5, 165.0, 159.9, 144.5, 130.0(2C), 
129.0, 115.5(2C), 111.5, 39.5; EI-m/z found 250.9708 (34.6%, M+), (C11H10FN3OS requires M 
251.0529); HPLC purity: 99.1% (tr = 9.2 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)pyrazine-2-carboxamide (PCM1-051) 
Yellow solid (0.08 g, 57%); m.p. 176-180 ⁰C; Rf  (CH3OH-CH2Cl2 2.0 : 8.0) 0.10; IR 
vmax(KBr)/cm
-1 3422 (N-H, 1⁰ amine), 2924 (C-H, aminomethyl CH2), 1675 (C=O, amide), 1546 
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(C=C, aromatic); δH (400 MHz; [D6]DMSO) 9.30 (1H, s, H3), 8.88 (2H, s, H4), 8.79 (1H, s, H5), 
7.15 (1H, s, H1), 3.95 (2H, s, H2); δC ([D6]DMSO) 162.9, 159.5, 148.6, 140.0, 144.6(2C), 144.2, 
111.6, 39.7; EI-m/z found 234.8896 (100%, M+), (C9H9N5OS requires M 235.0528); HPLC 
purity: 99.9% (tr = 3.4 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-1-benzyl-3-methyl-1H-pyrazole-5-carboxamide (PCM1-
083) 
White solid (0.0814 g, 35%), m.p. 158-160 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.17; IR 
vmax(KBr)/cm
-1 3431 (N-H, 1⁰ amine), 3060 (C-H, aromatic), 2931 (C-H, aminomethyl CH2), 
1669 (C=O, amide), 1549 (C=C, aromatic); δH (400 MHz; CD3OD) 7.29-7.16 (5H, m, H5, H6, 
H7), 7.07 (1H, s, H1), 6.84 (1H, s, H3), 5.73 (2H, s, H8), 4.03 (2H, s, H2), 2.30 (3H, s, H4); δC 
(CD3OD) 159.5, 158.1, 147.9, 145.5, 137.5, 134.7, 128.1 (2C), 127.3 (2C), 127.0, 113.7, 108.1, 
53.9, 39.4, 11.8; EI-m/z found 327.0607 (100.0%, M+), (C16H17N5OS requires M 327.1154); 
HPLC purity: 97.4%   (tr = 10.23 min). 
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N-(4-(Aminomethyl)thiazol-2-yl)-3-tert-butyl-1-phenyl-1H-pyrazole-5-carboxamide 
(PCM1-085) 
Brown solid (0.1446 g, 54%), m.p. 85-88 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.31; IR 
vmax(KBr)/cm
-1 3379 (N-H, 1⁰ amine), 3056 (C-H, aromatic), 2970 (C-H, tert-butyl CH3), 2927 
(C-H, aminomethyl CH2), 1680 (C=O, amide), 1542 (C=C, aromatic); δH (400 MHz; CDCl3) 
7.56-7.43 (3H, m, H7, H8), 7.31 (2H, d, J = 7.5 Hz, H6), 7.26 (1H, s, H9), 6.81 (1H, s, H1), 6.61 
(1H, s, H4), 4.92 (2H, br s, H3), 3.77 (2H, s, H2), 1.18 (9H, s, H5); δC (CDCl3) 159.7, 158.7, 
156.0, 146.6, 141.3, 129.9, 128.8 (2C), 128.3 (3C), 110.4, 105.4, 40.2, 32.2, 30.5 (3C); EI-m/z 
found 355.1451 (98.5%, M+), (C18H21N5OS requires M 355.1467); HPLC purity: 99.1% (tr = 
13.79 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-1-benzyl-3-p-tolyl-1H-pyrazole-5-carboxamide (PCM1-
087) 
Brown solid (0.0921 g, 14%), m.p. 85-87 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.30; IR 
vmax(KBr)/cm
-1 3414 (N-H, 1⁰ amine), 2953 (C-H, methyl), 2922 (C-H, aminomethyl CH2), 1678 
(C=O, amide), 1551 (C=C, aromatic); δH (300 MHz; CD3OD) 7.74 (2H, d, J = 8.2 Hz, H4), 7.38 
(1H, s, H1), 7.33-7.13 (8H, m, H3, H5, H7, H8, H9), 5.84 (2H, s, H10), 4.14 (2H, s, H2), 2.36 (3H, 
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s, H6); δC (CD3OD) 162.0, 159.9, 158.9, 151.0, 143.9, 139.9, 138.8, 129.9, 129.0 (2C), 128.1 
(2C), 127.1 (2C), 125.3 (3C), 112.5, 105.4, 54.5, 38.7, 19.9; EI-m/z found 403.0529 (27.1%, 
M+), (C22H21N5OS requires M 403.1467); HPLC purity: 95.9% (tr = 7.30 min). 
 
5.22 General procedure for the synthesis of pyrazole thiazole methylcarbamates (PCM1- 
         054 and PCM1-082) 
The pyrazole thiazole methylcarbamates (PCM1-054 and PCM1-082) were prepared following 
a general procedure detailed in section 5.10 with slight modifications. The reactions typically 
involved coupling of the appropriate pyrazole carboxylic acid to the amino intermediate PCM1-
028 (section 5.9) in presence of EDCI and DMAP. After completion of reaction as signalled by 
TLC, the reaction mixture for analogue PCM1-054 was concentrated in vacuo and directly 
subjected to column chromatography (SiO2, 0 – 40% EtOAc/Hexane) to give the desired product 
as a white solid. The aqueous work up in this case was deliberately avoided to circumvent the 
opportunity of losing part of the desired product into the aqueous phase. Due to poor solubility of 
the pyrazole carboxylic acid starting material, intermediate PCM1-082 was prepared by carrying 
out the reaction in DMF followed by precipitation of the product by addition of deionised water. 
The precipitate was filtered and sequentially washed with deionised water, hexane, and a 
minimal amount of EtOAc to deliver the pyrazole intermediate PCM1-082 as a brown solid. 
 
 
tert-Butyl (2-(3-tert-butyl-1H-pyrazole-5-carboxamido)thiazol-4-yl)methylcarbamate  
(PCM1-054) 
White solid (1.0244 g, 42%), δH (400 MHz; CDCl3) 7.35(1H, s, H7), 6.80 (1H, s, H1), 6.72 (1H, 
s, H4), 5.24 (1H, br s, H6), 4.50 (2H, br s, H2), 1.48 (9H, s, H3), 1.34 (9H, s, H5). 
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tert-Butyl (2-(1H-pyrazole-5-carboxamido)thiazol-4-yl)methylcarbamate (PCM1-082) 
Brown solid (0.3875 g, 55%), δH (400 MHz; [D6]DMSO) 7.83(1H, br s, H6), 7.24 (1H, br s, H5), 
7.02 (1H, br s, H4), 6.84 (1H, s, H1), 4.14 (2H, s, H2), 1.39 (9H, s, H3). 
 
5.23 General procedure for the synthesis of benzyl pyrazole thiazole methylcarbamates 
        (PCM1-055, PCM1-057, PCM1-064, PCM1-067, PCM1-071 and PCM1-088) 
The methylcarbamate intermediates PCM1-055 - PCM1-071 and PCM1-088 were synthesised 
by respectively stirring the pyrazole precursors PCM1-054 and PCM1-082 (1.0 eq) with the 
appropriate benzyl bromide (2.0 eq) in presence of K2CO3 (2.0 eq) base in DMF or acetonitrile at 
room temperature. Save for PCM1-055 and PCM1-057 whose reactions were performed in 
acetonitrile, DMF was used in all the reactions. The reaction mixture was stirred for 12 – 48 h, 
concentrated in vacuo, and partitioned between deionised water and dichloromethane. The 
organic layer was dried (MgSO4), concentrated in vacuo, and subjected to column 
chromatography (SiO2, 0-30% EtOAc/hexane) to afford the title compounds. PCM1-071 was, 
however, further purified by preparative-TLC in 30% EtOAc/hexane after failed column 
chromatographic separation. 
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tert-Butyl (2-(3-tert-butyl-1-(4-chlorobenzyl)-1H-pyrazole-5-carboxamido)thiazol-4 yl) 
methylcarbamate (PCM1-055) 
White solid (0.0713 g, 26%), δH (400 MHz; CDCl3) 7.25-7.14 (4H, m, H6, H7), 6.78 (1H, s, H1), 
6.63 (1H, s, H4), 5.98 (2H, s, H8), 4.90 (1H, br s, H9), 4.28 (2H, s, H2), 1.45 (9H, s, H3), 1.33 
(9H, s, H5). 
 
 
tert-Butyl (2-(1-(4-bromobenzyl)-3-tert-butyl-1H-pyrazole-5-carboxamido)thiazol-4yl) 
methylcarbamate (PCM1-057) 
White solid (0.1040 g, 48%), δH (400 MHz; CDCl3) 7.35 (2H, d, J = 8.5 Hz, H7), 7.20 (1H, s, 
H1), 7.08 (2H, d, J = 8.5 Hz, H6), 6.50 (1H, s, H4), 6.08 (2H, s, H8), 4.09 (2H, s, H2), 1.44 (9H, s, 
H3), 1.31 (9H, s, H5). 
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tert-Butyl (2-(3-tert-butyl-1-(2-chlorobenzyl)-1H-pyrazole-5-carboxamido)thiazol-4- 
yl)methylcarbamate (PCM1-064) 
White solid (0.0417 g, 18%), δH (400 MHz; CDCl3) 7.38 (1H, dd, J = 8.5, 1.4 Hz, H6), 7.20-7.08 
(2H, m, H7, H8), 7.00 (1H, d, J = 7.7 Hz, H9), 6.81 (1H, s, H1), 6.53 (1H, s, H4), 6.03 (2H, s, H10), 
4.94 (1H, br s, H11), 4.24 (2H, d, J = 8.0 Hz, H2), 1.43 (9H, s, H3), 1.29 (9H, s, H5). 
 
 
tert-Butyl (2-(3-tert-butyl-1-(2,4-difluorobenzyl)-1H-pyrazole-5-carboxamido)thiazol-4  
-yl)methylcarbamate (PCM1-067) 
White solid (0.0651 g, 27%), δH (400 MHz; CDCl3) 7.26 (1H, s, H1), 7.12 (1H, m, H6), 6.90-6.67 
(2H, m, H7, H8), 6.64 (1H, s, H4), 5.99 (2H, s, H9), 4.94 (1H, br s, H12), 4.26 (2H, s, H2), 1.45 
(9H, s, H3), 1.34 (9H, s, H5). 
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tert-Butyl (2-(3-tert-butyl-1-(4-tert-butylbenzyl)-1H-pyrazole-5-carboxamido)thiazol-4- 
yl)methylcarbamate (PCM1-071) 
White solid (0.0683 g, 28%), δH (400 MHz; CDCl3) 7.25 (2H, d, J = 8.0 Hz, H6), 7.15 (2H, d, J = 
8.0 Hz, H7), 6.79 (1H, s, H1), 6.57 (1H, s, H4), 5.95 (2H, s, H9), 4.98 (1H, br s, H10), 4.30 (2H, br 
s, H2), 1.45 (9H, s, H3), 1.31 (9H, s, H5), 1.26 (9H, s, H8). 
 
 
tert-Butyl (2-(1-benzyl-1H-pyrazole-5-carboxamido)thiazol-4-yl)methylcarbamate (PCM1-
088) 
Whitish oil (0.1709 g, 34%), δH (400 MHz; CDCl3) 7.54 (1H, s, H5), 7.48-7.05 (6H, m, H4, H6, 
H7, H8), 6.93 (1H, s, H1), 5.95 (2H, s, H9), 4.95 (1H, br s, H10), 4.32 (2H, br s, H2), 1.45 (9H, s, 
H3). 
 
5.24 General procedure for the synthesis of aminomethylthiazole pyrazole carboxamides 
        (PCM1-056 - PCM1-073 and PCM1-089) 
The final target compounds PCM1-056 - PCM1-073 and PCM1-089 were synthesised by 
deprotection of their N-boc-protected precursors (PCM1-055, PCM1-057, PCM1-064, PCM1-
067, PCM1-071 and PCM1-088) by treatment with TFA. A general procedure described in 
section 5.4 of this dissertation was followed. 
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N-(4-(Aminomethyl)thiazol-2-yl)-3-tert-butyl-1-(4-chlorobenzyl)-1H-pyrazole-5-
carboxamide (PCM1-056) 
White solid (0.0181 g, 22%), m.p. 115-117 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.07; IR 
vmax(KBr)/cm
-1 3435 (N-H, 1⁰ amine), 3103 (C-H, aromatic), 2966 (C-H, tert-butyl CH3), 1667 
(C=O, amide); δH (400 MHz; CD3OD) 7.22 (2H, d, J = 8.6 Hz, H6), 7.20 (1H, s, H1), 7.14 (2H, d, 
J = 8.7 Hz, H5), 6.50 (1H, s, H3), 6.09 (2H, s, H7), 4.06 (2H, s, H2), 1.32 (9H, s, H4); δC (CD3OD) 
165.1, 160.9 (2C), 143.8, 136.8, 132.0, 129.8, 128.3 (2C), 128.0 (2C), 113.5, 104.2, 50.7, 39.2, 
30.5, 29.0 (3C); EI-m/z found 403.0546 (24.9%, M+), (C19H22ClN5OS requires M 403.1234); 
HPLC purity: 98.7% (tr = 7.52 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-1-(4-bromobenzyl)-3-tert-butyl-1H-pyrazole-5-
carboxamide (PCM1-059) 
Brown solid (0.0138 g, 16%), m.p. 92-94 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.21; IR 
vmax(KBr)/cm
-1 3414 (N-H, 1⁰ amine), 3099 (C-H, aromatic), 2961 (C-H, tert-butyl CH3), 2927 
(C-H, aminomethyl CH2), 1667 (C=O, amide); δH (400 MHz; CD3OD) 7.36 (2H, d, J = 8.5 Hz, 
H6), 7.21 (1H, s, H1), 7.09 (2H, d, J = 8.5 Hz, H5), 6.50 (1H, s, H3), 6.08 (2H, s, H7), 4.09 (2H, s, 
H2), 1.32 (9H, s, H4); δC (CD3OD) 164.1, 160.9 (2C), 143.3, 137.3, 131.2, 130.9 (2C), 129.0 
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(2C), 120.3, 113.7, 104.3, 50.9, 39.1, 29.3, 29.1 (3C); EI-m/z found 447.0108 (24.1%, M+), 
(C19H22BrN5OS requires M 447.0728); HPLC purity: 98.1% (tr = 8.02 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-3-tert-butyl-1-(2-chlorobenzyl)-1H-pyrazole-5-
carboxamide (PCM1-066) 
White solid (0.0160 g, 50%), m.p. 143-145 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.25; IR 
vmax(KBr)/cm
-1 3422 (N-H, 1⁰ amine), 3086 (C-H, aromatic), 2961 (C-H, tert-butyl CH3), 1637 
(C=O, amide); δH (400 MHz; CD3OD) 7.37 (1H, d, J = 7.9 Hz, H5), 7.29 (1H, s, H1), 7.22-7.11 
(2H, m, H6, H7), 6.90 (1H, d, J = 7.7 Hz, H8), 6.43 (1H, s, H3), 4.09 (2H, s, H2), 1.26 (9H, s, H4); 
δC (CD3OD) 161.1, 142.4 (2C), 135.5, 132.0, 129.0 (2C), 127.8 (2C), 126.7, 126.4, 114.5, 104.0, 
50.1, 38.7, 30.5, 29.0 (3C); EI-m/z found 403.0250 (37.1%, M+), (C19H22ClN5OS requires M 
403.1234); HPLC purity: 96.6% (tr = 7.14 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-3-tert-butyl-1-(2,4-difluorobenzyl)-1H-pyrazole-5-
carboxamide (PCM1-069) 
White solid (0.0130 g, 68%), m.p. 149-153 ⁰C; Rf  (CH3OH-CH2Cl2 1.4 : 8.6) 0.40; IR 
vmax(KBr)/cm
-1 3427 (N-H, 1⁰ amine), 3091 (C-H, aromatic), 2966 (C-H, tert-butyl CH3), 1671 
(C=O, amide); δH (400 MHz; CD3OD) 7.21 (1H, s, H1), 7.05 (1H, m, H5), 6.95-6.73 (2H, m, H6, 
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H7), 6.52 (1H, s, H3), 6.11 (2H, s, H8), 4.05 (2H, s, H2), 1.32 (9H, s, H4); EI-m/z found 405.1111 
(39.7%, M+), (C19H21F2N5OS requires M 405.1435); HPLC purity: 97.3% (tr = 7.95 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-3-tert-butyl-1-(4-tert-butylbenzyl)-1H-pyrazole-5-
carboxamide (PCM1-073) 
Brown solid (0.0285 g, 52%), m.p. 118-120 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.20; IR 
vmax(KBr)/cm
-1 3435 (N-H, 1⁰ amine), 2957 (C-H, tert-butyl CH3), 2927 (C-H, aminomethyl 
CH2) 1669 (C=O, amide); δH (400 MHz; CD3OD) 7.26 (2H, d, J = 8.3 Hz, H5), 7.18 (1H, s, H1), 
7.04 (2H, d, J = 8.3 Hz, H6), 6.40 (1H, s, H3), 6.04 (2H, s, H8), 4.06 (2H, s, H2), 1.30 (9H, s, H4), 
1.25 (9H, s, H7); δC (CD3OD) 161.2, 149.9, 144.8, 143.0, 134.8, 126.9, 126.2 (2C), 125.0 (2C), 
113.3, 103.9, 51.0, 39.3, 33.1, 31.3, 30.3 (3C), 29.0 (3C); EI-m/z found 425.1754 (26.5%, M+), 
(C23H31N5OS requires M 425.2249); HPLC purity: 95.4% (tr = 7.69 min). 
 
 
N-(4-(Aminomethyl)thiazol-2-yl)-1-benzyl-1H-pyrazole-5-carboxamide (PCM1-089) 
Yellow solid (0.0300 g, 23%), m.p. 166-169 ⁰C; Rf  (CH3OH-CH2Cl2 1.0 : 9.0) 0.25; δH (400 
MHz; CD3OD) 7.80 (1H, s, H4), 7.44-7.05 (6H, m, H3, H5, H6, H7), 6.93 (1H, s, H1), 5.48 (2H, s, 
H8), 4.11 (2H, s, H2); δC (CD3OD) 160.3, 159.1, 144.4, 143.3, 136.2, 132.4, 128.5 (2C), 128.0 
(2C), 127.4, 112.1, 107.4, 56.0, 38.8; EI-m/z found 313.0404 (100.0%, M+), (C15H15N5OS 
requires M 313.0997); HPLC purity: 97.2% (tr = 6.42 min). 
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5.25 Procedure for biological assays 
Compounds were tested in triplicate against chloroquine-sensitive (CQS) strain of Plasmodium 
falciparum (NF54). A modified method of Trager and Jensen1 was used to maintain continuous 
in vitro cultures of asexual erythrocyte stages of P. falciparum. Antiplasmodial activity in vitro 
was quantitatively assessed via the parasite lactate dehydrogenase assay using a modified 
method described by Makler et al.2 For each sample a 20 mg/ml stock solution in DMSO was 
prepared and sonicated to enhance solubility. Samples were tested as a suspension if not 
completely dissolved. Stock solutions were stored at -20 ºC and further diluted on the day of the 
experiment. Chloroquine (CQ) and artesunate were used as the reference drugs. 
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